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“Verlichting is het zegevieren van de mens over zijn zelfverkozen onmondigheid. 
Onmondigheid is het gebrek aan vermogen zijn eigen verstand te gebruiken zonder 
andermans leiding. Deze onmondigheid is zelfverkozen als de oorzaak niet een gebrek aan 
verstand is, maar gebrek aan moed om het verstand te gebruiken. Voor verlichting is niets 
anders vereist dan vrijheid, die vrijheid welke inhoudt dat men in elk opzicht openbaarlijk van 
zijn verstand gebruikmaakt. Want het is de roeping van ieder mens om zelf te denken.” 
 


























Aan Joost en mijn ouders 
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ANF   Anti nuclear factor 
anti-dsDNA  Anti-double stranded DNA 
anti-scl70  Anti-scleroderma 70 
anti-Sm   Anti-Smith 
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ATP   Adenosine triphosphate 
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EMR   Electromagnetic radiation 
FAD   Flavin adenine dinucleotide 
FASL   FAS-ligand 
FMN   Flavin mononucleotide 
ICAM-1   Intercellular adhesion molecule-1 
IFN-γ   Interferon gamma 
IgE   Immunoglobulin E 
LP   Lichen planus 
LFA-1   Lymphocyte function-associated antigen-1 
MED   Minimal erythemal dose 
MMP   Matrix metalloproteinase 
MOS SF36  Medical Outcome Study 36-item short-form 
NAD(H)  Nicotinamide adenine dinucleotide, oxidized form (reduced form) 
NADP(H)  Nicotinamide adenine dinucleotide phosphate, oxidized form  (reduced form) 
PBMCs   Peripheral blood mononuclear cells 
RIA   Radio immuno assay 
RNA   Ribonucleic acid 
RNP   Ribonucleoprotein 
ROS   Reactive oxygen species 
SCLE   Subacute cutaneous lupus erythematosus 
SCORAD  Scoring atopic dermatits 
SLAM   SLE Activity Measure 
SLE   Systemic lupus erythematosus 
SLEDAI  SLE Disease Activity Index 
UVA-1   Ultraviolet A-1 
VAS   Visual analogue score 
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UVA-1 therapy is a relatively new phototherapeutic modality. In this chapter, its position in 
the history of phototherapy, its physical properties and its biological effects are discussed. The 
objectives of this thesis are outlined at the end of this chapter. 
 
UVA-1 in the history of phototherapy 
 
The remedial use of sunlight has a long history. Egyptian and Indian healers used application 
of psoralen-containing plant extracts on the skin in combination with exposure to sunlight to 
heal leukoderma (vitiligo).1 Around 400 BC Greek athletes were recommended to sun-bathe 
before their competitions. According to Hippocrates, exposure to sunlight would activate 
‘body resources’ and restore ‘dyscrasia’ of the four body juices: yellow bile, black bile, 
phlegma, and blood.2 However, too much sun exposure was considered to cause disturbance 
of the well-regulated movement of fluids by thickening, resulting in 'constipation' instead of 
'purgation'. As an early form of photoprotection Plinius (23-79 BC) recommended to put the 
white of an egg on the face during sun-bathing.3 In the Middle Ages a white skin was 
fashionable. It proved that one belonged to the distinguished upper class, while a tanned skin 
identified the working class man. Consequently, heliotherapy (helios= sun) was not much 
used in that time. 
It was not until the end of the nineteenth century that real interest in phototherapy returned. 
Niels Finsen from Denmark developed light therapy for the treatment of lupus vulgaris 
(cutaneous form of tuberculosis), for which he received the Nobel Prize in 1903. From then 
on, the development of phototherapy accelerated. 
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However, the real 'boom' in phototherapy started in the late '70s. In 1974 Parrish et al. showed 
that ultraviolet A (UVA) irradiation of the skin preceded by orally administered 
8-methoxypsoralen was very effective in the treatment of psoriasis. This new therapy was the 
first form of photochemotherapy and became known as PUVA (psoralen and UVA 
radiation).4 Around the same time, also broad spectrum ultraviolet B (UVB) was shown to be 
able to clear several types of psoriasis. A decade later, a new type of lamps with an emission 
spectrum consisting of a narrow peak around 311/312 nm (narrow-band UVB) was added to 
the phototherapeutic arsenal.1 In that same period, Mutzhas et al. reported on new equipment 
emitting UV radiation in the 340-400 nm range.5 They used this long-wave UVA, later named 
“UVA-1”, successfully for provocation of polymorphic light eruption (PLE) and photopatch 
testing. It proved to be less effective in the treatment of acne and vitiligo. Little more had 
been heard of this UVA-1 radiation until 1992, when this UV source was shown to be 
successful in the treatment of atopic dermatitis.6-8 At present, high dose (130 J/cm2) and 
medium dose (50 J/cm2) treatment schedules are used in UVA-1 therapy for atopic dermatitis 
and other dermatoses. 
 
Physical properties of UV-radiation 
 
The existence of invisible rays of sunshine was not acknowledged until 1800, when infrared 
and UV-radiation were discovered. Until then, Newton (1669) considered light to consist of 
small particles. A decade later, Huygens (1677) formulated the theory that light consisted of 
waves, like waves of water. This was much later supported by Hertz (1888), who showed that 
any electromagnetic radiation (EMR) consists of waves, but that no medium is needed for its 
propagation. In 1905 Einstein proved light to be a discontinuous sequence of small energy 
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states (photons) and not visible matter. It was not until the second half of the last century that 
quantum physics were able to combine these two theories into a single “Theory of light”. 
Nowadays, sunlight is defined as electromagnetic radiation (EMR), consisting of photons 
with varying, wave-length dependent, energy levels.9 
According to wavelength, and accompanying physical and biological characteristics, the 
electromagnetic spectrum can be divided into gamma radiation, X-rays, UV radiation, visible 
light, infrared radiation, and electrical/radio waves (Fig. 1.1). The solar spectrum consists of 
UV, visible, and infrared radiation, but only 3-7% of solar radiation energy reaching the 
surface of the earth is UV radiation. This radiation can be subdivided into vacuum UV 
(10-200 nm), UVC (200-290 nm), UVB (290-320 nm), and UVA (320-400 nm). Vacuum 
UV-radiation derives its name from the fact that these wave-lengths are absorbed by oxygen 
and consequently not transmitted through air. UVC is almost totally absorbed by the (intact) 
ozone layer. UV radiation that reaches the earth essentially consists of UVB and UVA, the 
biologically most active components. 
Gamma




10 200 290 320 340 400 760
Wavelength (nm)
 
Figure 1.1. Subdivision of electromagnetic radiation 
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Physical properties of UVA-1 radiation 
 
Recently, UVA-1 (340-400 nm) has been distinguished from the rest of the UV spectrum for 
its different qualities and distinctive therapeutic potential.5-8 The longer wave-length of 
UVA-1 penetrates deeper into the skin and is therefore able to reach the deeper layers of the 
dermis and possibly the subcutis. In contrast, UVA-2 and UVB can penetrate only the upper 
layers of the dermis.10,11 These differences in penetration depths are in conflict with the 
differences in the energy levels: 
 
The equation:  E= hc/λ, 
 
in which E is energy, h is Planck’s constant (6.63 x 10-34J/s), c is the speed of light in meters 
per second and λ is the wave-length in meters, shows that the longer wave-lengths of UVA-1 
contain lower energy when compared with UVA-2 or UVB. One would expect that radiation 
with higher energy would penetrate deeper in the skin. However, the ability of UVB, UVA-2, 
and UVA-1 to penetrate the skin is principally determined by the concentration of UV 
absorbing compounds in the skin. There are much more UVB than UVA absorbing molecules 
in the epidermis, which is the reason why UVA (and especially UVA-1) radiation can reach 
the deeper layers of the skin. 
Different UVA-1 cabins have slightly different emission spectra, which may account for 
different treatment results. For most of our studies we used a BioSun Med UVA-1 cold-light 
unit (BioSun Sylt-Service, Wennigstedt/Sylt, Germany) (Fig. 1.2.). The apparatus emits 
photons with wavelengths of 340-550 nm and the usual irradiance was around 30 mW/cm2. 
Owing to a special filter system that eliminates all heat producing infrared radiation and a 
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ventilation system providing a cool breeze, this UVA-1 therapy is also called UVA-1 cold 
light therapy. From the same company we used a Photomed hand-UVA-1 unit (BioSun 















Figure 1.2. BioSun Med UVA-1 cold light unit 
 
Biological effects of UVA-1 
 
The biological effects of UV radiation are the consequence of the absorption of photons by 
molecules in the skin, so-called chromophores. These chromophores may transform into new 
molecules, called photoproducts. Some photoproducts are removed by repair mechanisms, 
others affect signal transduction pathways or are toxic to the cells. The resulting biological 
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effects can be visible within minutes (as in solar urticaria), hours (sunburn), or it may take 
days (e.g. activation of subacute cutaneous lupus erythematosus), or even years (photoaging) 
before they are discernible. 
Different wave-lengths are absorbed by different chromophores. The effects of UVA-1 
absorption by its chromophores (Table 1.1) are not yet fully known. 
 
Table 1.1. UVA-1 chromophores (see list of abbreviations) 
UVA-1 chromophores: 
Pyridine (NAD/NADH, NADP/NADPH) 
Riboflavin (FAD, FMN) 
Porphyrin 
Tryptophan 
Pteridine (folic acid) 
Urocanic acid12 




However, there is strong evidence that UVA radiation is an oxidizing component of sunlight 
that exerts its biological effects mainly by producing reactive oxygen species (ROS).13,14 The 
ROS production is based on photosensitizing properties of some absorbing compounds. Well-
known examples of natural photosensitizers are porphyrins and riboflavins, which after UV 
absorption in the presence of oxygen, produce singlet oxygen (1O2) and the superoxide radical 
(O2-). The latter is converted by the enzyme superoxide dismutase to hydrogen peroxide. The 
concentration of UVA-1 absorbing photosensitizers is highest in mitochondria and so it is 
obvious that these organelles are very sensitive to UVA-1 radiation. The most important of 
the presently known effects of UVA-1 on the different cutaneous cell types and their clinical 
implications, are described in detail below, and are summarized in table 1.2. 
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UVA-1 effect on keratinocytes 
Not much is known about the biological effects of UVA-1 on epidermal keratinocytes. 
Several experiments suggest that UVA-1, although not as much as UVB, can lead to 
thickening of the epidermis.15-17 After 60 J/cm2 UVA-1 (i.e. >1,5 MED) on 3 consecutive 
days in 12 healthy subjects, a mean epidermal thickening of 11% was observed, compared 
with 25% increase of epidermal thickness after 1,5 MED of UVB.16 This observation is 
supported by results of a cell-cycle study in mice. In these experiments, comparably 
erythematogenic doses of UVB and UVA-1 resulted in more cycling cells after UVB than 
after UVA-1,15 accounting for more pronounced epidermal hyperplasia after UVB than after 
UVA-1. Another explanation for epidermal thickening is provided by UV(B) induced small 
proline-rich protein 4 (SPRR4) which improves the epidermal integrity after UV exposure and 
prevents skin desquamation.18 
The intercellular adhesion molecule-1 (ICAM-1), expressed on the surface of keratinocytes is 
a cytokine-inducible adhesion molecule. It serves as a receptor, to which the leucocyte 
adhesion molecules lymphocyte function-associated antigen-1 (LFA-1 = CD11a/CD18 
integrin on leukocytes) and Mac-1 (= CD11b, α chain of integrin on macrophages) are able to 
bind.19,20 In this way ICAM-1 plays a role in the induction and maintenance of epidermal 
inflammatory infiltrates.21 Whereas normal skin is practically devoid of ICAM-1 expression 
on keratinocytes,22 expression of this molecule is found to correlate with the degree of 
inflammation in psoriasis and atopic dermatitis.22-24 After successful UVA-1 therapy for 
atopic dermatitis, ICAM-1 expression on keratinocytes was significantly reduced.25 
Downregulation of ICAM-1 expression by keratinocytes most probably results from 


































































































































































































































































































































































































































































































































































































   
18 
unlikely, particularly since UVA-1 irradiation of normal keratinocytes in vitro leads to singlet 
oxygen mediated ICAM-1 upregulation.65  
Next to a possible anti-inflammatory effect through the reduction of ICAM-1 expression on 
keratinocytes, UVA-1 has been shown to enhance mRNA levels of the anti-inflammatory 
cytokine IL-10 in human keratinocytes in vitro.26 However, this UV induced 
anti-inflammatory effect has never been confirmed on protein level in vivo. 
 
UVA-1 effect on Langerhans cells 
Various authors have reported that UVA-1 may affect epidermal Langerhans cells. In a paper 
by Dumay et al.,27 epidermal cell suspensions prepared from skin biopsies, taken three days 
after exposure to a single dose of UVA-1 (30 or 60 J/cm2) contained decreased numbers of 
Langerhans cells. Furthermore, a downregulation of antigen presenting cell function was seen, 
which could partially be prevented by prior application of a sunscreen.27 However, other data 
report that UVB, but not UVA-1 is capable of diminishing antigen-presenting cell function by 
interfering with the upregulation of CD80/86 molecules on Langerhans cells.30 Furthermore, 
after UVA-1 irradiation a decrease of Langerhans cell dendricity, rounding up of the cell 
body, mitochondrial membrane alterations and reticulo-endothelial dilation was observed, 
apart from a dose-dependent reduction of epidermal Langerhans cell density, for doses above 
30 J/cm2.29 Also, a decrease of Langerhans cells and dermal mast cells in the skin of atopic 
dermatitis patients was seen.28 None of the mentioned studies specifies whether the reduction 
of Langerhans cell numbers results from apoptosis or from migration. Together, these changes 
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UVA-1 effect on melanocytes 
Although observed in many of our patients, pigmentation of the skin resulting from UVA-1 
therapy is not frequently reported of in literature. Homogeneous hyperpigmentation was 
described in humans, after repetitive and single UVA-1 irradiations in 2 studies.32,66 Skin 
biopsies taken from these volunteers after a single UVA-1 irradiation showed increased 
numbers of epidermal melanocytes and enhanced melanin production.32 However, others 
noticed an increase of melanocytes in pigmented hairless mice after a single erythemal dose 
of UVB radiation, but not after even high doses of UVA-1.33 
Apart from an effect on melanocyte numbers a shift of epidermal melanocytes towards the 
dermis was observed.66 Some of these melanocytes exhibited fibrillar degeneration, others 
were morphologically intact. Fibrillar degeneration with consequent apoptosis can be 
considered a reaction to subtoxic cell damage.66 
As can be seen, not much is known about the effect of UVA-1 on melanocytes. More research 
needs to be done in this field. 
 
UVA-1 effect on T cells 
The dermal inflammatory infiltrate in patients with atopic dermatitis mainly consists of 
CD4-positive T-lymphocytes. These CD4-positive T-lymphocytes are also referred to as 
T-helper cells and can be subdivided in Th1 and Th2 cells according to their cytokine profile. 
Th1 cells mainly produce pro-inflammatory interferon gamma (IFN-γ), whereas Th2 cells are 
characterized by interleukin-4 (IL-4), IL-5, and IL-10 production. 
Grewe et al. observed that clinical improvement of atopic dermatitis was associated with a 
reduction of increased levels of IFN-γ mRNA.25 They also described that exposure of 
long-term cultured normal human keratinocytes to UVA-1 radiation caused an induction of 
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IL-10 mRNA expression and IL-10 protein secretion.26 IL-10 in turn, inhibits the production 
of IFN-γ by Th1 cells, which among other things, leads to decreased ICAM-1 expression on 
keratinocytes.21 As discussed earlier, ICAM-1 plays a role in the induction and maintenance 
of epidermal inflammatory infiltrates. 
Apart from the effect on T cell function and cytokine production, UVA-1 may also induce 
apoptosis of T helper cells.14,34 In vitro experiments have shown that UVA-1 induced T cell 
apoptosis is mediated by the generation of singlet oxygen and superoxide anions, as well as 
by increased FASL surface expression.13,14 Singlet oxygen is able to open mitochondrial 
megachannels, releasing apoptosis initiating factor and cytochrome c.35 The latter leads to 
activation of caspase pathways, which is followed by apoptosis. Additionally, the activation 
of the FAS/FASL system in T cells leads to receptor-triggered apoptosis. FASL binds to FAS, 
thereby stimulating a signaling pathway leading to apoptotic death of  of the FAS expressing 
cell. Through depletion of T cells in the dermal inflammatory infiltrate UVA-1 is thought to 
be effective in the treatment of various skin diseases with T cell involvement like atopic 
dermatitis,7,31 cutaneous T cell lymphoma,37-40 lichen ruber planus,41 sarcoidosis,67,68 
granuloma annulare,69 or pityriasis lichenoides.70 
 
UVA-1 effect on eosinophils 
UVA-1 has been shown to be able to lower the increased numbers of peripheral eosinophils 
and serum levels of eosinophilic cationic protein (ECP) in patients with atopic dermatitis.42,44 
As serum levels of ECP were proposed as a marker of disease activity,71 this effect could 
contribute to the positive effect of UVA-1 in the treatment of atopic dermatitis. The effect of 
UVA-1 on eosinophils is not only useful in atopic dermatitis. Plotz et al. observed 
improvement of skin lesions and relief of itching in patients with hypereosinophilic 
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syndrome, accompanied by reduction of peripheral eosinophil numbers and ECP.43 Recently, 
we have successfully used UVA-1 therapy in several patients with eosinophilic cellulitis 
(unpublished observation). The mechanism by which UVA-1 radiation generates its effect on 
eosinophils is unknown. 
 
UVA-1 effect on mast cells 
Immunohistochemical experiments show that the dermal mast cell is another potential target 
cell for UVA-1.28 A decrease of mast cell numbers was observed after high-dose UVA-1 
therapy (130 J/cm2) in the skin of patients with atopic dermatitis28and after both high- and 
medium-dose (60 J/cm2) UVA-1 therapy in cutaneous mastocytosis.45,46 An in vitro study 
showed that increasing doses of UVA-1 inhibited histamine release from human mast cells 
(HMC1 cell line).72 Patients with urticaria pigmentosa reported relief from itching, diarrhea, 
and migraine with normalization of histamine in 24-hour urine after high-dose UVA-1 
therapy.46 After both high- and medium-dose UVA-1 therapy, pruritus and quality of life 
improved significantly.45 
 
UVA-1 effect on fibroblasts 
Considering UVA-1 irradiation easily reaches the dermal part of the skin,11 dermal fibroblasts 
are another obvious target. Several in vitro and in vivo studies have shown a UVA-1 induced 
increase of interstitial matrix metalloproteinase (MMPs, i.e. MMP-1, MMP-2, MMP-3) 
mRNA47,48 and protein47 in human fibroblasts of healthy volunteers, morphea patients,49 and 
patients with systemic sclerosis.50,51 Mempel et al. have revealed a decrease of collagens I and 
III in skin biopsies of patients with atopic eczema after medium dose UVA-1 therapy.54 As 
mentioned earlier, UVA-1 can generate reactive oxygen species (ROS).13 Since it has been 
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shown that both induction of oxidative stress and exogenously added H2O2 to human dermal 
fibroblasts lead to increased collagenase (MMP-1) mRNA levels in vitro52,53 it is most likely 
that oxygen species are mediators of the UVA-1-induced synthesis of matrix 
metalloproteinases. 
The induction of collagenase, which degrades dermal collagen, may be an important mediator 
of photoaging (wrinkling)73,74 and may facilitate tumor invasion.52 Repeated suberythemal 
doses of (broad spectrum) UVA in vivo resulted in decrease of elastic fiber content, further 
contributing to photoaging.55 
The induction of collagenase can explain the effects of UVA-1 in the treatment of a number 
of sclerotic skin conditions, like localized scleroderma,56-58 scleroderma and acrosclerosis in 
patients with systemic sclerosis,50,75 sclerodermic type of graft versus host disease,59,60 
scleredema,76 and extragenital lichen sclerosus et atrophicus.77,78 UVA-1 mediated induction 
of other matrix-degrading enzymes, like proteoglycanase, leading to degradation of 
hyaluronic acid depositions is thought be responsible for the improvement of cutaneous 
lesions of patients with reticulate erythematous mucinosis (REM syndrome) after UVA-1 
therapy.79 
 
UVA-1 effect on endothelial cells 
Recently, it has been proposed by Breuckmann et al.  that apart from T cell apoptosis and 
collagenase induction, UVA-1 phototherapy possibly has a third mode of action in patients 
with sclerotic skin diseases. The authors showed that UVA-1 phototherapy resulted in 
increased vascular endothelial growth factor (VEGF) expression, leading to increased 
vascularization.36 This could also explain why we observed healing of therapy resistant 
General introduction 
   
23 
ulcerations in several patients with systemic sclerosis and in a patient with ulcerative 
sarcoidosis during UVA-1 therapy (unpublished observations). 
 
Carcinogenic properties of UVA-1 radiation 
The main short-term side effects of UVA-1 therapy are a minor erythema, tanning of the 
skin,66 and slight xerosis cutis. As explained in one of the previous paragraphs, repeated 
UVA-1 therapy could very well lead to premature skin aging. Another, important long-term 
risk is a potential carcinogenic effect. Some decades ago, UVA was regarded to be 
noncarcinogenic.80 Recent animal experiments have shown, however, that UVA-1 is able to 
induce skin cancer.81,82 
De Gruijl and coworkers accumulated many data on the induction of skin tumors by chronic 
UV exposure in albino mice. From these data they constructed an action spectrum for 
carcinoma induction. Maximum UV effectiveness for tumor induction was found to be at 
293 nm (=UVB), with a steep decrease to the UVA area.83 This striking difference in 
carcinogenicity between short- and long-wave UV radiation has been confirmed in various 
experimental situations. Indeed, repetitive exposure of healthy volunteers to 25 J/cm2 UVA-1 
resulted in nuclear p53 expression in epidermal keratinocytes,84 indicating DNA damage. 
However, much lower p53 expression was found in human epidermis after 2 and 3 MED of 
UVA-1 than after 2 and 3 MED of solar simulated irradiation or 3 MED of narrowband 
UVB.85,86 In another study, transient p53 expression was detected in murine epidermis in vivo 
after 1 MED of UVB and 2 MED of UVA-1 irradiation, but not after 1 MED of UVA-1 
irradiation.15 Furthermore, only an occasional sunburn cell was observed after repetitive 
exposure to 35 J/cm2 UVA-1 (365 nm).17 This finding was confirmed by Beattie et al.85 who 
showed that 3 MED of UVA-1 produced negligible numbers of sunburn cells in the epidermis 
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of volunteers, in contrast to 3 MED of narrowband UVB and 3 MED of solar simulated 
radiation. These apoptotic keratinocytes are thought to be other markers of DNA damage. So, 
there is accumulating experimental evidence that UVA-1 is less carcinogenic than UVB and 
UVA-2. 
The difference in extent and type of carcinogenic outcome between UVA and UVB can be 
explained by their different wavelength-specific effects. UVB acts mainly through direct 
damage of DNA bases, leading to the formation of pyrimidine dimers, potential sources of 
mutations. UVA-1 irradiation, on the other hand, is not absorbed by DNA. Still it has been 
reported that it is capable of inducing pyrimidine dimers,87 but approximately 10,000 times 
less efficiently than UVB and 100 times less efficiently than UVA-2.33 In the UVA-1 part of 
the spectrum the most important mechanism of DNA damage is based on the fact that reactive 
oxygen species, formed during photosensitisation of endogenous chromophores, may attack 
and damage DNA molecules.88 
Many researchers believe that UV  radiation is strongly implicated in the etiology of 
cutaneous melanoma. However, the most harmful wavelength has not been identified with 
certainty. The well-known experiments with a pigmented fish model (Xiphophorus) provided 
the first indications that UVA radiation (and visible light) were effective in the induction of 
(fish) melanoma.89 However, the results of two recent studies have suggested that UVB, and 
not UVA or UVA-1, plays an important role in the induction of melanomas. Only 
UVB-containing sources (isolated UVB and solar simulator) initiated melanomas in 
hepatocyte growth factor/scatter factor (HGF/SF) transgenic mice, whereas broad band UVA 
and a sunlamp, filtered to remove 96% of the UVB, did not.90 In the second study, melanocyte 
proliferation in hairless mice was observed only after the irradiation with erythemal doses of 
UVB, but not after high doses of UVA-1.33 However, there are also other data that show that 
General introduction 
   
25 
not only UVB (304 nm), but also UVA-1 (365 nm) was effective in causing an increase of 
melanocyte numbers in volunteers.32,66 So it seems that the role of UVA-1 in melanoma 
induction in humans still remains speculative. 
In conclusion,  although UVA-1 appears to be less genotoxic than the other parts of the UV 
spectrum, it is not harmless. It is very important not to underestimate its potential 
carcinogenic effects, particularly since the doses used for treatment are sometimes high, and 
because the long-term effects of UVA-1 irradiation are still unknow. 
 
Objectives of the thesis 
 
The main goal of the studies presented in this thesis was to examine the efficacy of UVA-1 
therapy in several diseases characterized by the involvement of T and/or B cells. Whereas so 
far many reports have focused on working mechanisms of UVA-1 therapy in T cell mediated 
skin conditions, similar studies in SLE, a B cell mediated disease, are almost lacking. The 
second goal of our studies therefore was to clarify some of the mechanisms underlying the 
beneficial effects of UVA-1 therapy in SLE patients. 
 
The majority of published data concern atopic eczema, in which efficacy of UVA-1 is beyond 
doubt. Some authors have reported good results with high-dose (130 J/cm2, 3 weeks) UVA-1 
in the treatment of atopic dermatitis,6 whereas others reported that also medium doses of 
UVA-1 (50 J/cm2, 3 weeks) could be successfully applied.91 In order to better determine the 
place of UVA-1 in the dermatological therapeutic arsenal, its efficacy has to be compared 
directly with other treatment modalities and different UVA-1 treatment schedules must be 
evaluated. Tzaneva et al. observed that after the usual successful 3 weeks of medium dose 
Chapter 1 
   
26 
UVA-1 therapy, eczema relapsed relatively soon.92 To investigate whether the prolongation of 
treatment leads to a longer therapeutic response we treated 32 patients with atopic dermatitis 
with medium dose UVA-1 during 4 weeks and compared the clinical effect with the usual 
3 weeks’ schedule (29 patients) (Chapter 2). Considering the large impact of this disease on 
patients’ quality of life, the effect of UVA-1 therapy on quality of life was also assessed. 
The efficacy of UVA-1 therapy was also examined in patients with therapy resistant 
acrovesicular dermatitis of the hands (Chapter 3). The only report so far on positive effects 
of UVA-1 in the treatment of chronic dyshidrotic hand eczema regarded an uncontrolled study 
of 12 patients.93 To confirm and expand these data we designed a controlled study in which 
UVA-1 therapy was compared with placebo therapy in 28 patients (Chapter 3). 
The results of UVA-1 treatment of patients suffering from generalized lichen ruber planus and 
the effect on histopathological changes in the skin are reported in Chapter 4. 
 
In the late 1980s, McGrath Jr et al. described a favourable effect of UVA radiation on SLE 
activity in a mouse model of SLE.94 Later, they reported encouraging results in SLE patients 
treated with UVA-1.61,62 These results were unexpected, as photosensitivity is a frequently 
occurring symptom in SLE and patients are recommended to avoid sun light. In addition, 
sunlight or exposure to artificial ultraviolet (UV) lamps is believed to be capable of activating 
systemic disease in these patients.95 Although the study designs had some shortcomings, the 
positive outcomes of the mentioned investigations encouraged us to design two studies to 
examine the efficacy of UVA-1 therapy in the treatment of patients with SLE. We treated 11 
and 12 patients respectively, with 2 doses of UVA-1 in two double blind, placebo controlled, 
cross-over studies (Chapters 5 and 6). Two validated scoring systems were used in order to 
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evaluate disease activity in SLE patients during both trials. In addition, we studied the effect 
of UVA-1 exposure on auto-antibody titers and on quality of life. 
In an attempt to elucidate the mechanism(s) behind the effects of UVA-1 in SLE, we 
performed an in vitro study which is described in Chapter 7. Questions addressed in this 
investigation concerned: (i) What percentage of UVA-1 actually reaches the dermis? (ii) Are 
peripheral blood mononuclear cells (PBMCs), and especially B cells, susceptible to UVA-1 
induced cytotoxicity? and (iii) Has UVA-1 radiation effect on immunoglobulin production by 
activated B cells? 
 
The results described in Chapters 2-7 are summarized and further discussed in Chapter 8. 
In addition, the position of UVA-1 therapy in the dermatological practice and some 
possibilities for future research are discussed in this chapter. 
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Background: UVA-1 has been shown to be effective in the treatment of patients with atopic 
dermatitis. However, its optimal therapeutic conditions are not yet fully established. 
Methods: In an open prospective study we retrospectively compared the effect of 4 weeks 
therapy (32 patients) with the effect of the usual 3 weeks therapy (29 patients) in patients 
with atopic dermatitis, using a medium dose UVA-1 cold light (45 J/cm2), 5 days a week. 
Results: Scoring atopic dermatitis index (SCORAD) and dermatology life quality index 
(DLQI) quality of life indexes improved significantly during both 3 and 4 weeks UVA-1. 
Patients who were treated for 4 weeks showed a superior improvement of the SCORAD index 
(23.12 points, 95% confidence interval (CI) 16.09-30.16, vs. 13.32 points, 95% CI 5.61-
21.04, p = 0.059), and the DLQI (5.41 points, 95% CI 2.38-7.88, vs. 3.86 points, 95% CI 
1.88-5.84, p = 0.360), compared with patients who were treated for 3 weeks. However, the 
differences did not reach statistical significance. Only patients who were treated for 4 weeks 
were able to maintain their improvement 6 weeks after therapy. In both groups 50% of 
patients had intermittently used mild topical corticosteroids in the follow-up period. 
Conclusion: Extension of UVA-1 therapy from 3 to 4 weeks results in a clinically relevant 








Since the 1970s psoralens and ultraviolet A radiation (PUVA) therapy has been successfully 
used for the treatment of atopic dermatitis. Alternative forms of phototherapy for the same 
disease have been UVB, narrow-band UVB and UVA-UVB combination therapy. In the 
1980s UVA-1 treatment was introduced. This long-wave (340-400 nm) UVA treatment 
appeared to be a promising phototherapeutic modality. Some authors have reported on good 
results of high-dose (130 J/cm2, 3 weeks) UVA-1 in the treatment of atopic dermatitis,1 
whereas others have shown that also medium doses of UVA-1 (50 J/cm2, 3 weeks) could be 
successfully applied.2 In several controlled trials, both high- and medium-dose UVA-1 
proved to be more effective than UVA-UVB combination therapy.1-4 
We observed (Fig. 2.1.), together with some other authors that after a successful 3 weeks of 
medium dose UVA-1 therapy, eczema deteriorated relatively soon.5 To investigate if the 
prolongation of treatment leads to a longer therapeutic response we treated 61 patients with 
atopic dermatitis with medium-dose UVA-1 during either 3 or 4 weeks, and we evaluated 
disease activity, quality of life and duration of improvement after a follow-up period of 
6 weeks. 
 
Patients and methods 
 
In an open prospective study 32 patients with atopic dermatitis were treated with UVA-1 
during 4 weeks. Their therapeutic effect was retrospectively compared with the effect of 
UVA-1 in 29 patients who were treated during the usual 3 weeks. The mean age of patients 
was 33.4 years (range 17-73), 19 were male, 42 were female. The majority of the patients had 
skin type II (24/61), or III (29/61). The remaining eight patients had skin type I (4/61) or V 
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(4/61) Patients with moderate to severe atopic dermatitis [Scoring atopic dermatitis index 
(SCORAD) range 14.8-76.2] with insufficient effect of local corticosteroids, and no use of 
systemic corticosteroids or cyclosporine therapy in the previous 2 months, were included. 
A Photomed 250 000 unit (BioSun Sylt Service GmbH, www.biosunsylt.com), emitting 
photons with wave-lengths of 340-500 nm, with an irradiance of 31 mW/cm2, was used. 
Owing to a filter system that eliminates all infrared (i.e. heat producing) radiation and a 
ventilation system providing a cool breeze, this UVA-1 therapy is also called UVA-1 
cold-light therapy. 
Patients were treated with 45 J/cm2, 5 days a week, during 3 (29 patients) or 4 (32 patients) 
weeks. In the first week, the UVA-1 dose was increased from 3 J/cm2 on Monday to 15 J/cm2 
on Tuesday, and further increased by 10 J/cm2 every day to a maximum of 45 J/cm2 on 
Friday. The cumulative UVA-1 doses were 573 and 798 J/cm2 for the 3 and 4 weeks 
treatment schedule, respectively. During therapy patients wore goggles. Before the treatment, 
weekly during treatment, and 3 weeks and 6 weeks after treatment, two scoring systems were 
applied: the SCORAD (maximum possible score 103) 6 and the Dermatology Life Quality 
Index (DLQI, maximum possible score 30 = maximal discomfort).6,7 The examination of both 
scoring systems was performed by the same investigator who evaluated these parameters also 
in the 3 weeks’ treated patients. 
Except for the first week during which the daily dose was gradually increased to 45 J/cm2, 
patients used no topical steroids or antihistamines until the follow-up. Emollients could be 
used infinitely until 3 h before irradiation to prevent glimmering of the skin and consequent 
radiation reflection. Temperature on the skin surface was measured after 10 min to compare 
with heat producing qualities of PUVA units reported in literature.8 
A paired t-test was used to assess changes in the SCORAD index, and the DLQI during and 




weeks treatment regimen. Analyses were performed according to the intention to treat 




UVA-1 treatment resulted in a statistically significant decrease of the SCORAD index at the 
end of therapy [18.5 points, p = 0.0001, 95% confidence interval (CI) 13.26-23.67]. Baseline 
SCORAD (p = 0.75) and DLQI (p = 0.59) indexes of the 3 weeks’ treated patients did not 
differ from those of 4 weeks’ treated patients. The patients who had been treated for 4 weeks 
achieved better results (mean decrease of 23.12, SD = 19.52 , p < 0.001, 95% CI 16.09-30.16) 
than those treated for 3 weeks (mean decrease of 13.32 points, SD = 20.28, p = 0.001, 
95% CI 5.61-21.04) (Fig. 2.1.). However, this difference was just not statistically significant 
(p = 0.059, 95% CI –20.00-0.40). Furthermore, when both groups had been treated for 
3 weeks, the difference in improvement of the SCORAD index was not statistically 
significant (p = 0.256). After a 6 weeks’ follow-up period 50% of patients were lost to 
follow-up in both groups. These patients had not responded better or worse to UVA-1 therapy 
than the patients who were not lost to follow-up. At that moment in time the SCORAD index 
of patients in both groups had increased by five points, which corresponded to a 21.6% loss 
of post-treatment effect for the 4 weeks’ treated group and a 37.5% loss of post-treatment 
effect for the patients who were treated for 3 weeks. The patients from the 4 weeks treatment 
regimen still showed a significant improvement of their SCORAD index compared with 
pretreatment values, whereas those who were treated during 3 weeks did not (Fig. 2.1.). 
In both groups approximately 50% of patients had intermittently used mild topical 
corticosteroids during the follow-up period. The patients who did not need topical 
corticosteroids during follow-up had not responded better or worse to UVA-1 therapy than 
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the patients who did use local corticosteroids during follow-up. The DLQI showed a 
significant decrease after both 3 (3.86 points, SD = 5.20, p<0.000, 95% CI 1.88-5.84) and 
4 weeks (5.41 points, SD = 7.53, p = 0.001, 95% CI 2.38-7.88) of UVA-1 therapy. The effect 
of two treatment regimens did not differ significantly (p = 0.360, 95% CI –1.81-4.90). Similar 
to the SCORAD index, only patients who had been treated for 4 weeks were still significantly 
improved at 6 weeks after therapy (Fig. 2.2.). 
UVA-1 cold light therapy was generally well tolerated by patients. During treatment the 
maximum temperature at body distance was 34°C (range 24-34°C). In PUVA-cabins 
temperatures up to 41°C were reported.8 Some side-effects occurred. Fifteen (24.6%) patients 
experienced slight erythema in the first week that did not require any treatment and resolved 
spontaneously in a few days. This could be explained by the relatively light skin type of these 
patients (2/15 skin type I, 11/15 skin type II, 2/15 skin type III). Eight patients (13.1%) 
dropped-out: Two of them developed a photosensitive reaction (one had solar urticaria, the 
other probably had a light phototoxic reaction because of cosmetics), six others exacerbated 
after 1 (n= 2) and 2 weeks (n= 4). Their inferior therapeutic results might explain the large 







With the use of medium doses of UVA-1 a mean improvement of SCORAD indices of 38% 
after 3 weeks was comparable with the results reported in literature.9-11 A four weeks’ 
treatment regimen appeared to result in a better outcome immediately after therapy than the 
3 weeks’ regimen. Although not statistically significant, the authors find the difference 
clinically relevant. Furthermore, compared with the 3 weeks’ regimen, the maintenance of 
achieved clinical results during follow-up was improved. The 1-week extension of therapy 
might thus partly overcome the problem of deterioration of eczema after three weeks of 
medium dose UVA-1 as also reported by others.5 However, as both groups deteriorated 
five points during the 6 weeks’ follow-up period, the authors realize that the improved 
maintenance of therapeutic results in the 4 weeks’ treated group is partly explained by the 
superior improvement of the SCORAD and DLQI indexes immediately after therapy in the 
4 weeks’ treated group. The question remains whether the demanding treatment schedule, 
i.e. 5 days a week, is necessary and whether less frequent irradiations (2-3 /week) would have 
similar therapeutic effects. 
PUVA therapy is a frequently used form of phototherapy in the treatment of atopic dermatitis. 
So far, there have been no studies published comparing the efficacy of UVA-1 with PUVA in 
the treatment of atopic eczema. Photosensitivity caused by psoralens requires protection of 
the eyes and the skin against sunlight during the rest of the day. Furthermore, up to 20% of 
patients suffer from side-effects of oral psoralens.12 In our study, apart from some slight 
erythema in the first week and a photosensitive reaction in two patients, no short-term 
side-effects were seen. 
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Figure 2.1. Mean Scoring atopic dermatitis index (SCORAD) ± standard deviation during 3 
and 4 weeks UVA 1 and follow-up. 3 after/6 after: 3 and 6 weeks after UVA-1 therapy, 
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Figure 2.2. Mean dermatology life quality index (DLQI) ± standard deviation during 3 and 
4 weeks UVA-1 and follow-up. 3 after/6 after: 3 and 6 weeks after UVA-1 therapy, 




PUVA and UVA-1 have different cellular targets. In PUVA therapy, psoralens bind to DNA 
molecules, followed by a UVA-induced photochemical reaction that is taking place in close 
vicinity of DNA molecules. Consequently, it is not surprising that long-term repetitive PUVA 
results in an increased risk of skin cancer.13,14 UVA-1 photons are not absorbed by nucleic 
acids. The most important targets of UVA-1 radiation are located in the mitochondria that 
contain relatively large concentrations of UVA-1 absorbing co-enzymes of the redox chain. 
DNA damage is mediated indirectly by the production of radical oxygen species. Although 
animal studies suggest that UVA-1 is less carcinogenic than UVA-2 and UVB,15 the 
long-term carcinogenic hazards of UVA-1 remain to be clarified and should not be 
underestimated. Some authors also showed that UVA-1 is capable of inducing squamous cell 
carcinoma in mice.16,17 This radiation can induce expression of p53 and pyrimidine dimers in 
human skin and in murine skin, however much less effectively than UVB and solar simulated 
radiation.18-20 It is not yet clear whether UVA-1 plays a role in the etiology of melanoma. 
A recent experimental work has brought some evidence that UVB, but not UVA irradiation 
initiated melanoma in transgenic mice.21 
UVA-1 radiation has been shown to generate singlet oxygen and superoxide anions.22,23 
Extensive production of such reactive oxygen species can, apart from contributing to 
carcinogenity, in certain cell types, lead to apoptotic death.24 Lymphoid cells have frequently 
been used for the investigation of UVA-mediated apoptotic responses because of their lower 
threshold for switching to the UV-induced apoptotic program.22,25 At least part of the 
therapeutic response to UVA-1 radiation could thus be ascribed to an apoptosis-inducing 
effect on the inflammatory infiltrate and especially on T-helper cells.23,26 
Our work supports the earlier studies of others showing that UVA-1 therapy can be 
successfully used as a monotherapy in the treatment of atopic dermatitis. For the prolongation 
of its therapeutic effects, a 4 weeks’ treatment regimen is preferable to a 3 weeks’ regimen. 
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Still , the place of UVA-1 in the treatment of atopic dermatitis needs to be better defined, e.g. 
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Abstract 
We carried out a randomized, double-blind, placebo-controlled study to examine the 
therapeutic effect of UVA-1 irradiation on dyshidrotic hand eczema. Twenty-eight patients 
were randomised to receive UVA-1 irradiation (40 J/cm2) or placebo, five times a week for 
3 weeks. Evaluated by the DASI and the VAS, UVA-1 was significantly more effective after 
2 and 3 weeks. Also, desquamation and area of affected skin improved significantly more 
after UVA-1. We did not find any difference regarding the response of patients with increased 
IgE blood levels (>100 IE/ml) compared with those having normal IgE concentrations. No 
side effects were observed. This study indicates that UVA-1 can cause a significant 
improvement of both objective and subjective signs of dyshidrotic eczema. 
 




Dyshidrotic eczema is a chronic symptomatic palmoplantar dermatitis. Frequently, patients do 
not respond properly to topical treatment and occasionally systemic corticosteroids are 
needed. Photo(chemo)therapy can be effective in dyshidrotic eczema, and in particular, 
PUVA has been reported to have some beneficial effect.1-3 However, the use of psoralens is 
associated with increased carcinogenic risk. The absence of psoralen in UVA-1 therapy 
represents a significant advantage over PUVA. The first trial of UVA-1 in the treatment of 
chronic vesicular dyshidrotic eczema of the hands was reported in an uncontrolled study of 
12 patients.4 As patients with dyshidrotic eczema may experience spontaneous remissions, 
efficacy of UVA-1 needed to be tested in a controlled manner. Here we describe the results of 
a double-blind, placebo-controlled study in which we examined the effectiveness of UVA-1 
phototherapy. 
 
Patients and methods 
 
Patients 
In the period of November 1999 until March 2001, 28 patients with dyshidrotic eczema of the 
hands were included in a randomized double-blind, placebo-controlled study after approval of 
the research project by the ethics committee of the hospital. Patients younger than 18 years 
and patients who used systemic immunosuppressive or immnunomodulating medication in the 
2 months prior to participation were excluded. Other exclusion criteria were pregnancy and a 
history of UV-sensitivity or skin malignancy. Patients signed informed consent forms before 
participating in the study. They were randomly assigned to either UVA-1 (n=15) or placebo 
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treatment (n=13) by an independent investigator using a lottery system. A blinded investigator 
was responsible for the evaluation of the parameters. 
The average duration of the patients’ complaints was 8 years and 4 months (range, 4 months–
34 years). All had used potent topical steroids prior to the study, with little or no apparent 
benefit. There was no washout period for topical steroids. Seven patients had been 
successfully treated with PUVA in the past, but this had been delivered at least 6 months prior 
to UVA-1 therapy. 
 
Irradiation equipment 
A Photomed CL 3000 cold-light unit (Photomed World Industries, Hamburg, Germany, 
irradiance 60 mW/cm2) was used as hand irradiation equipment emitting photons with 
wavelengths of 340-500 nm. Owing to a filter system that eliminates all infrared irradiation 
and a ventilation system providing a cool breeze, Photomed UVA-1 therapy is also called 
UVA-1 cold-light therapy. Placebo treatment comprised of TL tubes, emitting visible light, 
covered with a blue plastic plate to mimic the blue UVA-1 light. During both treatments 
patients wore protective eyewear and their forearms were protected against scattered 
radiation. 
 
Treatment schedule and evaluation 
Patients were treated with 40 J/cm2 UVA-1 or with placebo using the same irradiation time 
(11 min), 5 times a week for 3 weeks. The primary endpoint was the DASI (dyshidrotic area 
and severity index, maximum score 60). It consisted of the sum of the severity scores of 
vesicles (V), erythema (E), desquamation (D) and itch (I) (0 = none, 1 = mild, 2 = moderate, 
3 = severe), multiplied by the surface of the affected area of the hand (A) (1= <20%, 
 
   
53 
to 5 = 81-100%).5 Secondary endpoints were a VAS (visual analogue score) for itch 
(maximum  10) and the separate items of the DASI. All parameters were determined before 
treatment, at the end of each week, and 3 and 6 weeks after treatment. Photographs were taken 
before and after 3 weeks of irradiation. Furthermore, we compared the effect of UVA-1 in 
non-atopic patients with that in atopic patients, the latter defined as those with increased IgE 
levels. During the entire treatment period patients used no topical steroids or antihistamines. 
No emollient was applied in the 3 h before irradiation. 
 
Statistical methods 
A paired t-test was used to assess changes in the DASI, its subscores and the VAS for itch 
during and after treatment. A nonpaired t-test was used to evaluate differences between the 
effect of UVA-1 and placebo treatment. Analysis was performed according to the 




UVA-1 treatment resulted in a statistically significant mean decrease of the DASI of 6.5 
points (SD 5.7) at the end of the second week and of 8.7 points (SD 6.7) at the end of the third 
week. Placebo showed a mean increase of DASI of 1.1 points (SD 7.3) and 0.4 points 
(SD 8.9) respectively. Difference between both regimens reached statistical significance at the 
end of the second and third week (p = 0.006 and p = 0.005, respectively) (Fig.3.1.). After 
therapy, there was also a significantly greater mean reduction of DASI subscores of 
desquamation (p = 0.005), itch (p = 0.005), and the affected skin area (p = 0.039) in the 
UVA-1 treated group when compared to the placebo treated patients. Although the mean 
DASI subscore of vesicles demonstrated 
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Figure 3.1. Changes in mean DASI score with standard deviations (SD) in patients with 
dyshidrotic hand eczema as a result of phototherapy with UVA-1 radiation and placebo light. 
 
 
















DASI 8.67 (6.72) 4,95-12,39 0,000* -0,38 (SD 8,87) –5,75-4,98 0,878 
Desquamation 0.53 (0.74) 0,12-0,94 0,015* -0,46 (SD 0,97) –1,05-0,12 0,111 
Itch 0.8 (0.68) 0,43-1,17 0,000* -0,23 (SD 1,09) –0,89-0,43 0,461 
Affected area 0.6 (0.63) 0,25-0,95 0,003‡ 0,08 (SD 0,64) –0,31-0,46 0,673 
Vesicles 0.73 (0.88) 0,24-1,22 0,006 0,69 (SD 1,32) –0,1-1,49 0,082 
Erythema 0.4 (0.91) –1,0-0,9 0,111 0,08 (SD 0,86) –0,44-0,6 0,753 
VAS 2.31 (2.01) 1.16-3.42 0.001* -1,37 (SD 4,05) –3,82-1,08 0,26 
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a statistically significant reduction during UVA-1 (p = 0.006), there was no difference 
between UVA-1 and placebo. At the same time, there was a clear reduction (p = 0.005) in the 
mean VAS for itch in the UVA-1 group when compared to placebo (Table 3.1). 
Nine patients had increased serum IgE (>100 IU/ml) levels. The four of them belonging to the 
UVA-1 group did not respond better or worse to UVA-1 than the patients with IgE serum 
concentrations within the normal range (p = 0.4). Four patients in the UVA-1 group who were 
previously successfully treated with PUVA did not respond better to UVA-1. 
For ethical reasons some patients (mainly from the placebo group) could not be withheld from 
using topical corticosteroids after the 3 weeks of phototherapy. Six weeks after therapy the 
mean DASI in the UVA-1 treated group still showed a mean improvement of 10,85 points 
(SD 6,35). Although we could not properly evaluate the duration of the therapeutic effect, 
some patients probably need corticosteroid maintenance therapy to sustain the effect of 
UVA-1. 
Apart from some minor erythemal reactions, no side-effects occurred. Three of the 13 patients 




UVA-1 radiation has been shown to be effective in the treatment of several skin diseases such 
as atopic dermatitis, localized scleroderma and mycosis fungoides.6-8 Grattan et al. found 
topical PUVA and UVA to be equally effective in the treatment of dyshidrotic eczema.1 
However, UVA-1 and UVA have the advantage that no psoralens, with their side-effects and 
increased carcinogenic risk, are used. 
We have shown that UVA-1 is significantly more effective than placebo, and is very well 
tolerated. According to literature there are two main modes of action of UVA-1. One of them 
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is induction of apoptosis of lymphocytes in the inflammatory infiltrate through generation of 
reactive oxygen species9 and expression of FAS ligand on T lymfocytes.10 Lymphoid cells 
have frequently been used for the investigation of UVA-mediated apoptotic responses 
because of their lower threshold for switching to the apoptotic program.11 Secondly, in vitro 
UVA-1 irradiation of cultured keratinocytes resulted in increased interleukin (IL)-10 mRNA 
expression and protein secretion.12 As IL-10 is a Th-2 derived anti-inflammatory cytokine 
known to inhibit pro-inflammatory interferon-γ, this may explain the decrease in 
inflammation observed with UVA-1. 
In addition, UVA-1 appears to have a lower carcinogenic risk than PUVA and UVB. 
Compared with solar simulator light, UVA-1 induced less photodamage (pyrimidine dimers) 
in murine skin.13 Likewise, in human skin 1 and 2 minimal erythemal doses from a solar 
simulator gave rise to twice the levels of p53 induced by UVA-1.14 In another study, UVA-1 
also induced less tumour suppressor gene p53 than “broad” UVA.15 These observations 
indicate that UVA-1 causes less DNA damage. However, Lavker and coworkers have 
suggested that UVA-1 is capable of inducing dermal photo ageing.16 
In conclusion, UVA-1 appears to be an effective therapy for dyshidrotic hand eczema, 
particularly on itch and affected area of skin. As no significant side-effects were observed, 
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To the Editor: 
Although it is considered to be self-limiting, lichen planus (LP) may exist for many years and 
may be generalized and difficult to treat. Four patients with histologically proven, 
therapy-resistant, generalized LP were treated with Ultraviolet A1 (UVA-1). None used 
medication known to improve LP or induce lichenoid drug reactions. 
Treatment consisted of irradiation with 45 J/cm2 for 5 days per week during two 4-week 
treatment periods with a 3-week interval, with the Photomed 250 000 (Photomed World 
Industries, Hamburg, Germany) emitting 30 mW/cm2. Before and after treatment the affected 
body area, a 100-mm visual analogue score for itch and the Dermatology Life Quality 
Index (DLQI) were determined.1 
Case 1 was a 39-year-old woman who presented with a 4-month history of very itchy, 
generalized LP (Fig. 4.1a). Topical corticosteroids and retinoic acid had proven ineffective. 
After UVA-1 therapy 98% clearance was achieved (Fig. 4.1.b) and both itch and DLQI 
improved considerably. Thick plaques on her ankles resolved to thin patches. Histologically, 
all characteristic features of LP had normalized and only a sparse infiltrate was seen (Figs. 
4.2a and 4.2b). 
Case 2 was a 38-year-old man who presented with an 8-month history of hardly itching, 
generalized LP. Potent corticosteroid ointments were ineffective. After UVA-1 therapy, his 
LP had cleared for 88%. However, the patches on his ankles showed only some improvement. 
Cases 3 and 4 were a 54-year-old father and his 17-year-old daughter who had a history of 
generalized LP of 22 and 9 years, respectively, and had little effect from topical 
corticosteroids and tretinoin cream. Long-term psoralen plus UVA (PUVA) therapy had 
previously been successful for the father, but his LP was exacerbated during a second PUVA 
course. UVA-1 therapy resulted in 82% clearance. The daughter had some temporary 
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improvement with UVB treatment 7 years earlier. In her case, UVA-1 therapy resulted in 
41% clearance. The DLQI and the VAS improved in both. The thick patches on their ankles 
had not cleared completely. 
In all 4 patients therapy-resistant LP lesions improved significantly (Table 4.1). In the past, 
PUVA therapy has also shown to be effective in the treatment of LP.2 Biological effects of 
UV-rays are mediated by different photochemical mechanisms. UVA-1 radiation is known to 
generate singlet-oxygen and superoxide anions.3 Extensive production of such radicals can 
lead to apoptotic death of lymphoid cells4 that have been shown to have a lower threshold for 
switching to the apoptotic program.5 At least part of the therapeutic response to UVA-1 
radiation may thus be because of an apoptosis-inducing effect on the inflammatory infiltrate.3 
Whether other mechanisms also play a role in the therapeutic effect remains to be elucidated. 
UVA-1 therapy may be a promising additional therapy in the treatment of generalized LP, 
with no short-term side effects. Further studies with appropriate controls would be 
worthwhile. 
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Figure 4.1a Patient 1 before UVA-1 treatment  
Figure 4.1b She was tanned after treatment and on this part of the body  
only marked hyperpigmentation was left where the LP lesions had been 
 







Before UVA-1 the biopsy 
showed the characteristic 
histological features of LP 
Figure 4.2b 
After UVA-1 some post-
inflammatory hyperpig-
mentation and a very 
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Objective: Treatment of patients with systemic lupus erythematosus (SLE) often implies 
strong drugs with possibly serious side effects. Thus, there is a need for new 
immunosuppressive treatments. Long wave ultraviolet A (UVA-1) cold light therapy is an 
anti-inflammatory, immunomodulatory treatment with a possible systemic effect and few side 
effects. In the current study low dose UVA-1 cold light treatment was tested to determine 
whether it reduces disease activity in SLE. 
Methods: Eleven patients with SLE were treated with UVA-1 cold light treatment and a 
placebo light treatment in a double blind, placebo controlled, crossover study. In two 
consecutive 12 week periods the patients were treated in the first three weeks with UVA-1 
and placebo treatment or vice versa. The primary variables were the SLE Disease Activity 
Index (SLEDAI) and SLE Activity Measure (SLAM). 
Results: The mean SLAM and SLEDAI showed a significant decrease of 30.4% (p=0.0005) 
and 37.9% (p=0.016) respectively after three weeks of UVA-1, and a non-significant decline 
of 9.3% (p=0.43) and 12.2% (p=0.54) respectively after three weeks of placebo treatment. 
In this small trial the difference in reduction of the disease activity indices during UVA-1 
compared with during placebo treatment failed to reach the conventional border of 
significance (p=0.07). The total score of quality of life measure MOS SF36 did not improve 
significantly, but the subscore for vitality did improve. 
Conclusion: Low dose UVA-1 cold light treatment was strongly suggestive of lowering 
disease activity in this double blind , placebo controlled study, and no side effects occurred. 
 




Current treatment of systemic lupus erythematosus (SLE) comprises non-steroidal 
anti-inflammatory drugs (NSAIDs), antimalarial drugs, prednisone, azathioprine, 
cyclophosphamide, chlorambucil, and methotrexate. These are drugs with potential side 
effects. Thus there is a need for alternative immunosuppressive treatments. Long wave 
ultraviolet A (UVA-1) cold light therapy is an immunosuppressive treatment1,2 with proven 
efficacy in patients with atopic dermatitis.3 The main short term side effects are a little 
sunburn and slight xerosis cutis. Although animal experiments suggest that UVA-1 is less 
carcinogenic than UVA-2 and UVB,4 the severity of long term side effects, like 
carcinogenicity and aging, is not yet clear. Compared with UVB (280-320 nm) and UVA-2 
(320-340 nm), UVA-1 (340-400 nm) penetrates deeper into the skin, as far as the deeper 
layers of the dermis. Because of that deeper penetration the immunosuppressive and 
anti-inflammatory effects of UVA-1 are thought to be moderately systemic. 
For a long time exposure to sunlight has been associated with exacerbation of SLE.5,6 
Approximately 45% of patients with SLE are known to have photosensitivity.7 After exposure 
to sunlight patients show persistent erythema, erythematous papules or papulovesicles. 
Mainly UVB and, to a lesser extend UVA, are held responsible for the signs of 
photosensitivity occurring.8 Accordingly, the first reports on the beneficial effects of long 
wave UVA-1 in patients with SLE were unexpected. 
In 1987 McGrath Jr et al described the favourable effect of UVA on SLE activity. Survival 
was prolonged only in irradiated mice in the New Zealand black/New Zealand white mouse 
model of SLE. Irradiated mice, compared with those not irradiated, had decreased 
anti-dsDNA levels and decreased spleen size at necropsy. Irradiation comprised wavelengths 
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predominantly in the UVA range (320-400 nm).9 Later, these authors also reported that low 
dose UVA-1 induced decreases of clinical disease activity, doses of systemic steroids, and 
autoantibodies in humans and improved disease activity scores during maintenance treatment 
when patients were irradiated twice a week for eight months after the initial three week 
treatment period.10,11 In 1993 Sonnichsen et al. published a case report about the successful 
treatment of a patient with subacute cutaneous lupus erythematosus with UVA-1.12  
As UVA-1 irradiation may be promising in the treatment of SLE and as studies to determine 
the efficacy of UVA-1 in the treatment of SLE have been carried out by one research group 
only, we treated 11 patients with SLE in a double blind, placebo controlled, crossover study to 
compare results and establish a basis for further clinical and laboratory investigation. 
 
Patients and methods 
 
Patients 
Eleven patients with mild to moderate SLE were included in this prospective study (Table 1). 
Patients (one male, 10 female) were recruited from the SLE outpatients’ clinic of the 
rheumatology department. Their mean age was 38.1 years (range 18-56, median 35). 
Nine patients were white subjects, one was Surinam creole, and one was Indonesian. At entry 
their disease had a mean duration of 7.8 years (range 2-19, median 6). All patients fulfilled 
four or more American College of Rheumatology criteria for the diagnosis SLE and an SLE 
Disease Activity Index (SLEDAI13) of at least four. Patients were not allowed to change their 
drugs two months before entry. During the study, changes in drugs (except for NSAIDs) 
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Irradiation equipment 
For UVA-1 irradiation the Photomed 250 000 (Photomed Medizintechnik GmbH Vertrieb 
Deutschland, Gehrden, Germany) was used. It emits photons with wavelengths longer than 
340 nm. The instrument is equipped with a filter system that eliminates all infrared radiation, 
which significantly reduces heat production and increases comfort for the patients. Owing to 
these filters, the ventilation system that provides the patient with a cool breeze, and the blue 
color of the light, Photomed UVA-1 treatment is also called UVA-1 cold light treatment. 
The placebo treatment comprised TL light tubes that could be placed under the UVA-1 light 
tubes. In this way patients used the same cabin for both treatments. To match the blue colour 
of the UVA-1 treatment, blue plastic covered the frame with the TL tubes. Patients could 
recognise differences between the lamps but they did not know which was the supposedly 
effective treatment. During both treatments patients wore protective eyewear. 
 
Treatment schedule 
The study had a double blind, placebo controlled, crossover design. During two consecutive 
12 week periods patients were treated in the first 3 weeks. The following 9 weeks served as a 
wash out period. Patients were randomly allocated to group A (n=9) or group B (n=2) by an 
independent person. Irradiation consisted of total body irradiation with 6 J/cm2, five days a 
week for three weeks or an equivalent time of exposure (3 minutes, 20 seconds) to placebo 
light. Group A was treated with UVA-1 for the first three weeks and was crossed over to be 
treated with the placebo light treatment in the second treatment period. Group B was treated 
with both UVA-1 and placebo light treatment in reverse succession. Irradiation was carried 
out during the winter months to minimise concomitant exposure to natural sunlight. Variables 
were evaluated every three weeks by the doctor until nine weeks after the last three week 
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treatment period. Both the doctor and the patients were blinded to the treatment throughout 
the study. 
Our primary measures were two systems for clinical assessment of SLE activity, the SLE 
Disease Activity Index (SLEDAI)13 and the SLE Activity Measure (SLAM).14 The SLEDAI 
consists of 19 items representing nine organ systems. Each item is rated as present or absent. 
The SLAM includes 24 clinical manifestations for nine organ systems and eight laboratory 
variables to evaluate organs that cannot otherwise be assessed. All items are scored as 0 to 2, 
or 0 to 3 according to their severity. Two 100 mm visual analogue scales (VAS) accompany 
the SLAM score to measure the patient’s and doctor’s subjective ratings of disease activity. 
We decided to use the SLEDAI score because it discriminates single disease activity states 
among subjects well and completion costs little time. We included the SLAM score because it 
detects a treatment effect more sensitively.14 Furthermore, drugs were monitored and the 
patients filled in a validated quality of life questionnaire, Medical Outcome Study 36-item 
short-form health survey (MOS SF36),15 at each control visit. This quality of life 
questionnaire was rated in total as well as in separate scores for different features of quality of 
life: physical, social, and mental functioning, pain, vitality, and change in state of health. 
Apart from evaluation of clinical variables, titres of antibodies to SSA, SSB, Sm and RNP 
were determined as well as antinuclear antibodies and anti-dsDNA. Furthermore, a complete 




McGrath found a 39% decrease (=6 points, SD 4.295, p<0.005) of disease activity scores in 
10 patients who were treated with UVA-1.11 To detect a decrease of six points when treated 
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with UVA-1 and 0 points when treated with placebo (SD 4.295) with a power of 80% 
(α=0.05, two sided tests) 11 patients were needed. A paired Wilcoxon test was used to 
determine changes in clinical and laboratory variables before and after UVA-1 and placebo 
irradiation and to determine significant differences (p<0.05) between improvement by UVA-1 





Of the 11 patients included in this study, none was lost to follow up. Clinical disease activity 
scores decreased more after three weeks of treatment with UVA-1 than after three weeks of 
placebo treatment. The mean SLAM showed a significant decrease of 30.4% (4.09 points, 
95% confidence interval (CI) 2.49 to 5.69) after three weeks of UVA-1 by decreasing from 
13.45 (=100%, SD (2.21)=16.43%) to 9.36 (=69.59%, SD (2.42)=17.99%) (p=0.0005) 
(Fig. 5.1.). Although the mean SLAM showed a non-significant decline of 9.3% (1.18 points, 
95% CI –1.89 to 4.26) from 12.73 (=100%, SD (3.35)=26.32%) to 11.55 (=90.73%, 
SD (3.56)=27.97%) (p=0.43) after three weeks of placebo treatment, the SLAM did not 
decrease significantly more after UVA-1 than after placebo treatment (mean -2.91, 95% CI 
-6.39 to 0.57, p=0.07). Similarly, the SLEDAI decreased by 37.9% (5.55 points, 95% CI 1.24 
to 9.85) after UVA-1 treatment and 12.2% (1.32 points, 95% CI -1.29 to 3.93) after placebo 
treatment, that is, from 14.64 (=100%, SD 5.12=34.97%) to 9.09 (=62.09%, 
SD 4.78=32.65%) after UVA-1 (p= 0.016) and from 10.82 (=100%, SD 5.78=53.41%) to 9.50 
(=87.8%, SD 3.93=36.32%) after placebo treatment (p=0.54) (Fig. 5.1.). Again, the difference 
between decrease of SLEDAI after UVA-1 and after placebo was not significant (mean -4.23,  
 


































Before treatment After treatment
p=0.0005 NS NSp=0.016
 
Figure 5.1. SLAM and SLEDAI showed statistically significant improvement  
during UVA-1. Improvement of these variables during placebo treatment was  
not statistically significant. 
 
95% CI-10.11 to 1.65, p=0.07). Until six weeks after UVA-1 the decrease of SLAM and 
SLEDAI was significant compared with the SLAM and SLEDAI scores before treatment. 
Thus, the clinical effect of UVA-1 lasted for six to nine weeks. SLAM and SLEDAI scores 
did not show significant decreases immediately after, three, six, or nine weeks after placebo 
treatment. 
The nine organ systems of the SLAM score were also evaluated separately. The score of 
integument (oral ulcers + cutaneous rash + vasculitis + alopecia) and the cardiovascular score 
(Raynaud + hypertension + carditis) showed significant improvement after UVA-1 cold light 
treatment in comparison with placebo treatment (p=0.04 and 0.03 respectively). These results 
were mainly due to improvement of rash (p=0.08) and Raynaud’s phenomenon (p=0.06). 
Improvements in the other seven organ systems were not statistically significant.  
Also, the MOS SF36 subscore for vitality improved more after UVA-1 (-15.91 points, from 
33.64 to 49.55, 95% CI -29.58 to -2.24) than after placebo treatment (2.27 points, from 47.27 
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to 45.00, 95% CI -8.60 to 13.14) (p=0.03). Changes in the MOS SF36 total score and in the 
remaining subscores after UVA-1 were not statistically significantly different from changes in 
these scores after placebo treatment. 
Four patients were anti-SSA positive. In these four patients a mean decrease of anti-SSA 
antibody titres of 2.75 U/ml was found after UVA-1 (from 87 to 84.25, 95% CI 3.25 x 10-2 
to 5.47) and a very small mean increase of 0.25 U/ml after placebo treatment (from 83 
to 83.25, 95% CI -3.26 to 2.76) was seen; the difference was not significant (p=0.06), 
however. Seroconversion from a positive to a negative anti-SSA status did not occur. 
Anti-dsDNA antibody status did not differ significantly throughout the study. Changes in the 
doctor’s and the patient’s VAS and changes in the complete blood count , the ESR, and the 
urine analysis after UVA-1 were not different from after placebo treatment. No changes in 
drugs were made. None of the evaluated variables showed a period or carry over effect. 
Despite the fact that five of the 11 patients were known occasionally to be photosensitive, no 




Improvement of SLAM and SLEDAI during UVA-1 treatment was significant, whereas 
improvement of both scores during placebo was not. Although the small number of patients 
resulted in a p value of 0.07, we suggest that the better improvement of the SLAM and 
SLEDAI during UVA-1 compared with during placebo treatment has obvious clinical 
importance. We make this suggestion especially because UVA-1 has few short term side 
effects and certainly the side effect profile is better than that of most of the alternative 
treatments for SLE. Apart from improvement of SLAM and SLEDAI scores, which contain 
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both objective and subjective variables, objective serological monitoring of disease activity by 
evaluating titres of anti-SSA showed and obvious trend of improvement during UVA-1 
treatment in the four anti-SSA positive patients included. 
The statistically significant improvement of the integument and cardiovascular subscores of 
the SLAM and of the vitality subscore of the MOS SF36 quality of life index should be 
interpreted with some caution. It should be kept in mind that testing of subscores increases the 
risk of statistical significance by chance. One could correct by Bonferroni correction, though 
this method is considered to be conservative. 
In a double blind, placebo controlled, crossover design McGrath et al. treated 26 patients with 
SLE with less favourable results.16 After UVA-1 treatment, group A showed a significant 
1.7 point decrease of the SLAM from 8.4 (2.9) to 6.7 (1.9) (p<0.05). Decrease of the SLAM 
in group B after UVA-1 was not statistically significant. The lack of wash out periods in their 
study risked carry over effects. Furthermore, the authors did not evaluate placebo effects by 
comparing the changes in SLAM after UVA-1 with the changes in SLAM after placebo 
treatment. In an uncontrolled study McGrath treated 10 patients with 6 J/cm2 UVA-1 (five 
times a week for three weeks).10 The treatment resulted in improvement of various clinical 
measures. However, these variables were not combined in a commonly used disease activity 
scoring system and were consequently not easily comparable with our results. Furthermore, a 
different type of UVA-1 lamp was used. 
The working mechanisms of UVA-1 are largely unknown. In the treatment of atopic 
dermatitis UVA-1 light is used in much higher doses.3 Apoptosis of certain T cell populations, 
resulting from singlet oxygen generation, is believed to play a part in this therapeutic effect. 
Owing to the apparent risk of photosensitivity in patients with SLE, we used a very low dose 
of UVA-1. No signs of photosensitivity occurred in any of our patients. Symptoms of 
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photosensitivity are reported to occur in patients with SLE when irradiated with UVA doses 
higher than 20 J/cm2,8 and thus a UVA-1 dose higher than 6 J/cm2 might result in a better 
outcome. Also, it is not known how long the clinical effect of UVA-1 in patients with SLE 
lasts once the treatment is stopped. In our trial the effect lasted for six to nine weeks. 
A maintenance treatment of one or two irradiations a week might possibly prolong clinical 
effectivity. 
The working mechanism of UVA-1, the effect of a higher dose of UVA-1, and the effect of 
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Objective: The assessment of the efficacy of therapy of patients with moderately active 
systemic lupus erythematosus (SLE) with low doses of UVA-1 cold light. 
Methods: A double blind, placebo-controlled, cross-over study design was used for the 
examination of the efficacy of low doses of UVA-1 radiation (12 J/cm2/day for 15 days) in 
12 patients. 
Results: UVA-1 treatment resulted in a significant decrease of well-validated disease activity 
indexes [the SLE activity measure (SLAM) (p<0.001) and the SLE disease activity index 
(SLEDAI) (p=0.007)], whereas neither score improved significantly during placebo treatment. 
Furthermore, UVA-1 therapy proved to be more effective (mean decrease 4.8 points) than 
placebo [mean decrease –1.7 points (i.e. an increase)] when measured by the SLAM 
(p=0.001, 95% CI -7.56 to -2.28), but not by the SLEDAI. Two patients had transient skin 
reactions at the beginning of treatment. 
Conclusion: UVA-1 therapy appears to be a useful adjuvant treatment modality for patients 
suffering from moderately active SLE. Its effect could possibly be explained by reduction of 
B-cell function or apoptosis of plasma cells. 
 




Systemic lupus erythematosus is an autoimmune disease characterized by the production of a 
large variety of autoantibodies by B cells, leading to inflammation in various organs.1 Current 
therapies, such as glucocorticoids, azathioprine and cyclophosphamide, are effective, but their 
side-effects may account for considerable organ damage in the course of the treatment.2 
One of the frequently occurring symptoms in SLE is photosensitivity. In addition, sunlight or 
exposure to artificial ultraviolet (UV) lamps is believed to be capable of activating the 
disease. Although the mechanisms of the photosensitive skin reaction and SLE activation may 
be different, both adverse effects of UV exposure are the reason why patients are 
recommended to avoid sun exposure. 
For that reason, it was quite unexpected when McGrath Jr et al.3 described a favourable effect 
of UVA radiation on SLE activity in a mouse model of SLE. Later, McGrath Jr et al.4,5 
reported encouraging results obtained in SLE patients treated with a long-wavelength fraction 
of the UVA spectrum (340-400 nm), called UVA-1. This part of UVA is known to have a 
positive immunomodulating effect in some inflammatory skin diseases.6,7 
We have recently reported on our first experience with whole-skin UVA-1 cold light 
treatment of SLE patients.8 Being aware of the risk of photosensitivity we originally exposed 
our patients to only 6 J/cm2 of UVA-1, five times a week. After 3 weeks of exposure the 
disease activity indexes SLE Activity Measure (SLAM)9 and SLE Disease Activity Index 
(SLEDAI)10 were lower than at the beginning of the phototherapy. However, some minor 
placebo response was observed as well, which possibly explains the lack of statistical 
significance when the effect of UVA-1 on SLAM and SLEDAI was compared with that of 
placebo treatment. No side-effects occurred during or after treatment. 
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These first results encouraged us to set up a new controlled clinical trial with the use of higher 
doses of UVA-1 cold light. 
 
Patients and methods 
 
After approval of the ethical committee we treated 12 patients with moderately active SLE, 
according to the revised criteria for SLE of the American College of Rheumatology.11 Patients 
with a minimal SLEDAI of 4, with no changes in therapy during the last 2 months and 
without discoid skin lesions were included after their written consent was obtained. 
A BioSun Med  CL 3000 cold-light unit (BioSun Sylt, Wennigstedt, Germany) was used for 
the irradiations. The apparatus emits photons with wavelengths of 340-500 nm. Owing to a 
filter system that eliminates all infrared irradiation and a ventilation system providing a cool 
breeze, this UVA-1 therapy is also called UVA-1 cold light therapy. Placebo treatment was 
carried out using a panel of thermoluminescent (TL) tubes covered with a blue plastic plate 
that could be inserted into the UVA-1 cabin, to mimic the blue UVA-1 light. Patients could 
recognize differences between the two treatments on account of the absence of the cool breeze 
and warmth during placebo therapy. However, they did not know which was the supposedly 
effective one. Patients were allocated by an independent investigator for total body 
irradiations with 12 J/cm
2
 UVA-1 (n=6) or an equivalent time of total body exposure 
(6minutes 40 s) to placebo light (n=6), five times a week for 3 weeks. After a 9-week 
wash-out period the patients received the alternative treatment. 
The primary parameters followed during the treatment were the SLAM and the 
SLEDAI. Furthermore, the Medical Outcome Study Short-form 36 (MOS SF36)12 was used to 
evaluate quality of life and autoantibody titres [antinuclear factor (ANF), anti-double-stranded 
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DNA (dsDNA), anti-SSA, anti-SSB, anti-ribonucleoprotein (anti-RNP), anti-Sm, anti-Scl70, 
anti-Jo-1] were measured. Apart from non-steroidal anti-inflammatory drugs (NSAIDs), 
patients were not allowed to change their medication during the whole trial period. 
A paired t-test was used to assess changes in the SLAM, SLEDAI and the MOS SF36 and 
auto-antibody titers during both treatments. A non-paired t-test was used to evaluate 
differences between the effect of UVA-1 and placebo treatment. Analysis was performed 
according to the intention-to-treat principle. A power calculation showed that 11 patients were 




Twelve Caucasian patients (10 women, 2 men, age 23–58 yr), with moderately active SLE 
were included. Their mean SLAM and SLEDAI at time of inclusion were 13,42 (range 8-23) 
and 13,33 (range 6-23) respectively. At enrolment, their therapy consisted of low-dose 
prednisone (5/12), azathioprine (6/12), antimalarial drugs (7/12) and NSAIDs (8/12) (Table 
6.1.). 
As shown in Fig. 6.1., UVA-1 treatment resulted in a statistically significant decrease of both 
SLAM and the SLEDAI at the end of the third week of therapy, whereas during placebo 
treatment neither score improved significantly. Furthermore, UVA-1 therapy (mean decrease 
4.8 points) proved to be more effective than placebo (mean decrease –1.7 points, i.e. an 
increase) when measured by the SLAM (p=0.001, 95% CI -7.56 to -2.28) (Table 6.2.). 
Frequently improving components were arthritis (6/9), myalgia/myositis (5/7), 






















































































































































































































































































































































































































































































































































































































































































































































































































































































UVA-1: SLAM Placebo: SLAM UVA-1: SLEDAI Placebo: SLEDAI
before after
p< 0.001 p= NS p= 0.007 p= NS
 
Figure 6.1. The effect of 3 weeks´ total body irradiation with UVA-1 cold light and placebo 
on SLE activity expressed in SLAM and SLEDAI scores. The results are expressed as means 
with standard deviations. NS= not significant. 
 
SLAM and SLEDAI scores at the beginning of the first treatment period did not differ from 
the scores at the beginning of the second treatment period (p=0.096), nor were these scores 
before UVA-1 different from before placebo treatment (p=0.479). 
There were no significant changes of the MOS SF36, the ESR, leukocyte and differential 
counts, and C3- and C4-levels during UVA-1 treatment. The anti-RNP titre in one patient 
decreased by 25 units (31%), the anti-SSA titer in another by 16 units (22%). 
Photosensitivity may occur in patients with SLE when irradiated with UVA doses higher than 
20 J/cm2.13 Two out of seven of our patients, known to be photosensitive, experienced some 
slight problems at the beginning of UVA-1 therapy, which consisted of a transient facial 
erythema in one and a minimal activation of subacute cutaneous lupus erythematosus (SCLE) 
in the other. In the latter patient the dose was subsequently reduced to 6 J/cm2 at the 
beginning of the second week and the skin changes slowly disappeared. 
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Whereas the dose of 6 or 12 J/cm2 of short-wavelength UV (UVB) would cause serious burns 
with many apoptotic cells in the superficial skin, the same dose of UVA-1 does not generate 
any visible macroscopic or microscopic changes in the epidermis or dermis. Since it is known 
that UVA-1 photons penetrate easily to the superficial dermis, one must consider the 
possibility that UVA-1 radiation, by generating oxidative stress, may affect the metabolism of 
B cells and/or T cells in the capillary network of the skin. 
SLE is one of the autoimmune diseases where expanded numbers of plasma cells are present 
in the blood. Recent investigations have shown that the number and frequency of circulating 
CD27high plasma cells is significantly correlated with SLE disease activity.14 We suggest that 
these cells may be (one of) the targets of UVA-1 and that the irradiation might be able to 
suppress B cell activity or induce apoptosis of circulating activated B lymphocytes in the 
dermal and subcutaneous capillaries, resulting in lowered autoantibody production and 
subsequently in reduced disease activity. Alternatively, the B cell/T cell interaction could be 
affected. 
SLAM appeared to be more suitable than SLEDAI for evaluation of therapeutic results over a 
course of time.9 This could explain why UVA-1 therapy proved to be more effective than 
placebo when measured by SLAM, but not when evaluated by SLEDAI. 
Our results show that UVA-1 irradiation is a safe, effective adjuvant treatment for patients 
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Previous studies have shown that low-dose UVA-1 total body irradiations were capable of 
improving disease activity in patients with systemic lupus erythematosus (SLE). We 
hypothesized that UVA-1-induced suppression of immunoglobulin production by activated 
B cells in the dermal capillaries could be (partly) responsible for this effect. Our experiments 
with donor skin demonstrated that approximately 40% of UVA-1 could penetrate through the 
epidermis. Irradiation of peripheral blood mononuclear cells (PBMCs) with 2 J/cm2 of 
UVA-1 resulted in 20% cell death. This toxic effect could totally be prevented by pre-
incubation of the cell cultures with catalase. This indicates that the generation of hydrogen 
peroxide plays a role in UVA-1 cytotoxicity. T cells and B cells appeared to be less 
susceptible to UVA-1 cytotoxicity than monocytes. With the use of a CD40-CD40L B cell 
activation method we measured immunoglobulin production after various doses of UVA-1 
irradiation (0-2 J/cm2). The dosis of 2 J/cm2 caused a significant decrease of IgM, IgG, IgA 
and IgE production under the conditions of IL-10 or IL-4 (IgE) stimulation. Although UVA-1 
can cause apoptosis of B lymphocytes, we show that relatively low doses of UVA-1 radiation 
also affect the function of these cells. Both effects may be responsible for the observed 
improvement of disease activity in SLE patients. 
 




Systemic lupus erythematosus (SLE) is a relatively common, chronic disease characterized by 
the production of multiple antibodies. Although the pathogenesis of this multiorgan disease 
remains unclear, B lymphocytes are held largely responsible for the immune dysregulation 
that underlies the disease process.1 A significant proportion of therapeutic strategies in SLE 
are based on decreased production or the selective removal of circulating autoantibodies.2,3 
About ten years ago, long-wave (340-400 nm) UVA radiation, designated as UVA-1, was 
introduced as a potential therapeutic modality for SLE patients.4-7 The development of this 
new approach in the treatment of SLE was quite contrary to the conventional knowledge of 
UV radiation being harmful to most patients with lupus erythematosus. The discovery by 
McGrath Jr and co-workers8 that UVA radiation had a favorable effect on disease activity and 
survival in a mouse model of SLE gave the first impetus to research in this new area. Later, 
promising results of uncontrolled and controlled studies of UVA-1 therapy in SLE patients 
were published by the same author.4-7 Decreased disease activity scores, sometimes 
accompanied by lowered auto antibody titres, were reported. From this work it has also 
become clear that UVA-1, but not UVB or visible light, was responsible for the beneficial 
effects. 
We have recently conducted two double-blind, placebo controlled crossover studies in 11 and 
12 SLE patients, respectively, using so-called UVA-1 cold light irradiation equipment.9,10 
Being aware of the risk of photosensitivity in SLE patients we applied a low dose (6 J/cm2 in 
the first, 12 J/cm2 in the second study) of UVA-1 radiation daily, 5 days a week for 3 weeks. 
Even though we used UVA-1 equipment different from the apparatus used by McGrath et al, 
we could confirm the beneficial effect of UVA-1 treatment on disease activity and the 
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absence of side effects in both studies. In four patients with anti-SSA antibodies decrease of 
titres was recorded after UVA-1 therapy in the first study.9 In the second study the anti-SSA 
titre of one patient and the anti-RNP titre of another showed a marked decrease.10 
Whereas the same dose of short-wavelength UV light (UVB) would cause serious burns with 
many apoptotic cells in the superficial skin, UVA-1 in such a dose does not generate any 
macroscopic or microscopic changes in the epidermis or dermis. In the present work we show 
that UVA-1 photons penetrate easily to the superficial dermis which enables them to affect 
the function of circulating lymphocytes, monocytes and other cells in the capillary network of 
the skin. In addition, we have found evidence that one of the mechanisms underlying the 
beneficial effect of UVA-1 in SLE patients could be a suppression of antibody production in 
activated B cells. 
 
Material and methods 
 
Penetration of UVA-1 through the epidermis 
Three pieces of normal Caucasian skin (skin type II-III) were received after cosmetic breast 
reduction. The skin was washed 3 times with phosphate buffered saline (PBS) and 
subcutaneous fat was mechanically removed with small scissors. Each piece of skin was cut 
into three smaller parts (approximately 1.5 x 1.5 cm) which were incubated overnight with 
3 ml dispase solution (Life Technologies B.V. Breda, The Netherlands) in a Petri dish at 4°C. 
The next day, the contents of the Petri dishes were further incubated for 1 hour at 37°C for 
1 hour, after which the dermis was separated from the epidermis with two small tweezers.11 
The epidermis was placed on a microscope cover glass (23 x 32 mm), washed with PBS to 
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remove the rest of the dispase solution and kept in a Petri dish with a small amount of PBS to 
prevent desiccation. 
The small pieces of epidermis were put on cover glasses and placed on the aperture of an 
ultraviolet A-1 (UVA-1) measurement device (BioSun Sylt Service GmbH). The epidermal 
sheets were large enough to cover the opening of the measurement device completely. By 
varying the distance between the lamps and the cell cultures, three different irradiances of 
UVA-1 (23, 31 and 47 mW/cm2) were applied and the percentage of penetrated UVA-1 
radiation was determined. A BioSun Med 500 000 UVA-1 cold-light unit (BioSun Sylt 
Service GmbH, Germany, www.biosunsylt.com) was used as a UVA-1 source for these 
penetration experiments. The same unit was used for the irradiation of SLE patients in our 
previous study.10 The irradiance measured behind an empty cover glass put on the device’s 
aperture was considered as being 100% penetration. Each measurement was performed in 
triplicate. 
 
Determination of UVA-1 toxicity on PBMCs in vitro 
The toxic effect of UVA-1 radiation was determined by evaluating the viability of irradiated 
peripheral blood mononuclear cells (PBMCs) with the use of trypan blue exclusion (Sigma, 
USA). The cells of three healthy volunteers were isolated from heparinized blood by Ficoll-
Hypaque density-gradient (ρ= 1.077 g/ml, Pharmacia Biotech, Uppsala, Sweden) 
centrifugation and cultured in 24-wells plates. The wells were exposed to 0.5-10 J/cm2 of 
UVA-1 radiation. To one of every three wells catalase (Sigma, USA), in a final concentration 
of 20 units/ml, was added prior to irradiation. Twenty-four hours after exposure to UVA-1 
10 µl of trypan blue solution was added to each well and the cells were transferred to counting 
chambers to be manually counted. Counts were performed in triplicate. 
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To detect differences in the susceptiblity to UVA-1 toxicity of the various cell populations of 
the PBMCs, the viability of UVA-1 irradiated CD3 positive (T cells), CD14 positive 
(monocytes), and CD20 positive cells (B cells) was determined. PBMCs were irradiated with 
0, 0.5, and 2 J/cm2 UVA-1. Twenty-four hours later, cell death in the different cell 
populations was identified by using propidium iodide and flow cytometric analysis.12 
 
Effect of UVA-1 on immunoglobulin production 
PBMCs were obtained from heparinized blood of six healthy donors by separation on Ficoll-
Hypaque (ρ= 1.077 g/ml, Pharmacia Biotech, Uppsala, Sweden) density-gradient 
centrifugation. 
PBMCs were cultured in T75 flasks (Greiner, Alphen aan den Rijn, The Netherlands), on a 
layer of γ-irradiated mouse fibroblasts transfected with human CD40L, or on nontransfected 
(control) mouse fibroblasts (L cells).13 They were maintained in Iscove’s modified 
Dulbecco’s medium with glutamax (IMDM; Gibco BRL, Breda, The Netherlands), 
supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; Gibco BRL), 100 IU/ml 
of penicillin and 100 µg/ml of streptomycin (Boehringer, Mannheim, Germany). 
Recombinant human cytokine IL-4 (200 units/ml) or IL-10 (50 ng/ml, PeproTech, Rocky Hill, 
NJ) was added to the cultures to evaluate the effect of these cytokines on immunoglobulin 
production. 
Fifty thousand PBMCs were cultured on a layer of 5000 γ-irradiated (70 Gy) feeder cells: 
L-CD40L cells or L cells. The cultures were carried out in triplicate in 96-well culture plates 
at 37 °C and 5% CO2 saturation. The total volume (cytokines included) was 200 µl. 
Half of the tissue culture plates were irradiated daily with 0.5 or 2 J/cm2 during the first week 
(i.e. 5 irradiations). After correction for the absorption of UVA-1 by the culture wells, these 
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doses corresponded to exposure times of 12 and 48 seconds, respectively. The other half of 
the culture plates received the same doses of UVA-1 during the second week of incubation. 
All supernatants were collected on day 15. IgM, IgG, and IgA production resulting from all 
conditions was measured by enzyme-linked immunosorbent assay (ELISA)14, IgE production 
was determined by radio immuno assay (RIA)15. A paired t-test was used to evaluate 
differences between immunoglobulin production after 0, 0.5, and 2 J/cm2 UVA-1 irradiation. 
Statistical significance was defined as p= 0,05. 
The experiments were repeated with and without catalase added to the culture wells 
30 minutes prior to UVA-1 irradiation. These cultures were irradiated in the second week of 
incubation. IgM, IgG, and IgA production resulting from these conditions was measured. 
Again, a paired t-test was used to evaluate differences between immunoglobulin production 





Penetration of UVA-1 through the epidermis 
In order to obtain an estimate of the proportion of UVA-1 radiation that can reach the 
superficial dermis where blood capillaries are present, we investigated the penetration of 
UVA-1 through the epidermis. Despite increasing irradiances, the penetration of UVA-1 
through the epidermis of donor skin remained constant for all skin pieces (Fig. 7.1). However, 
interindividual variations in UVA-1 penetration ranged from 25% to 50%. The average 
penetration calculated from a total of 27 measurements was 39 ± 12%, which implies that 
approximately 60% of UVA-1 radiation was absorbed by the epidermis. 
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Figure 7.1. Mean penetration of three different irradiances of UVA-1 (23, 31 and 
47 mW/cm2) through three different pieces of epidermis from normal Caucasian persons (skin 
type II-III). The columns show means ± SD. 
 
Determination of UVA-1 toxicity on PBMCs in vitro 
After we had determined that a considerable part of UVA-1 irradiation was indeed capable of 
reaching the dermal layers of the skin and its capillaries, we started studying the cytotoxic 
effect of UVA-1 on PBMCs in vitro. As determined by trypan blue exclusion, increasing 
UVA-1 doses resulted in an increasing portion of non-viable PBMCs (Fig. 7.2). Pre-
incubation of the cells with catalase totally prevented the toxic effects of UVA-1 radiation, 
suggesting the involvement of hydrogen  
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Figure 7.2. The cytotoxic effect of UVA-1 on PBMCs, expressed as the mean percentage of 
dead PBMCs determined by trypan blue exclusion, after a single irradiation with 0.5-10 J/cm2 
of UVA-1 radiation, in the presence and absence of catalase (20 units/ml). The values are 
shown as means ± SD. 
 
peroxide in UVA-1 toxicity. The shape of the toxicity curve of UVA-1 (Fig. 7.2) created the 
impression of a stepwise increase of cytotoxicity. This might be explained by the selective 
death of different PBMC subpopulations with increasing doses of UVA-1. Flow cytometric 
analysis was used to find out whether there were differences in the sensitivity of different 
PBMC subpopulations to low doses of UVA-1 radiation. The proportion of viable CD20 
positive cells (B cells) was constant at 0.5 and 2 J/cm2 and slightly increased at 10 J/cm2 
(Figs. 7.3a and 7.3b), whereas the proportion of CD3 positive cells (T cells) slightly 
increased. As the proportion of viable CD14 positive cells decreased with increasing UVA-1 
dose, monocytes seemed to be the most sensitive cells. 
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Figure 7.3a. FACS analysis detecting B lymphocytes (CD20), T lymphocytes (CD3) and 
monocytes (CD14) of PBMCs, before and after the UVA-1 irradiation (10 J/cm2) (as used for 
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Figure 7.3b. The proportion of viable CD3 positive (T-lymphocytes), CD14 positive 
(monocytes), and CD20 positive cells (B-lymphocytes) twenty-four hours after irradiation 
with 0, 0.5, 2, and 10 J/cm2 UVA-1, determined by flow cytometric analysis. The values are 
presented as means ± SD. 
 
Effect of UVA-1 on immunoglobulin production 
Since the B cell population appears to remain relatively invariable after low doses of UVA-1 
in vitro, we investigated whether these UVA-1 irradiations result in decreased 
immunoglobulin production by activated B cells in vitro. In order to examine the effect of 
UVA-1 radiation on immunoglobulin production in peripheral blood B cells, we used the 
well-established CD40L culture system.13 PBMCs were cultured on a layer of γ-irradiated 
mouse fibroblasts transfected with human CD40L, in the absence or presence of recombinant 
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showed that IL-4 is essential for IgE production and that IL-10 is a critical factor for B cell 
activation and subsequent IgM, IgG and IgA (but not IgE) production.16,17 In this culture 
system, B cell activation consists of a first period of proliferation (week 1) followed by a 
second period of differentiation and antibody production.13 Immunoglobulin production at the 
end of the first week of incubation was generally very low (not shown). In cultures of 
fibroblasts lacking CD40-L and in those without added cytokines immunoglobulin production 























Figure 7.4. IgM production in non-irradiated cultures, after 2 weeks incubation of CD40L 
positive fibroblasts and fibroblasts lacking CD40L, under IL-4 or IL-10 stimulated or 
nonstimulated culture conditions. Data are shown as means ± SD. 
 
The combination of CD40L with IL-10 resulted in significant production of IgM at this point 
in time. At day 15, IgE production was present in the IL-4 stimulated conditions, suggesting 
that isotype switching took place during the second week of incubation (not shown). 
Daily UVA-1 irradiation in the first week did not affect immunoglobulin production in the 
supernatants at day 15. However, UVA-1 exposure of the cultured cells during the second 
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week of incubation resulted in a dose-dependent decrease of IgM, IgG and IgA production in 
IL-10 stimulated conditions and IgE in IL-4 stimulated conditions (Fig. 7.5). 
To investigate whether the decrease of immunoglobulin production after UVA-1 can be 
prevented by catalase, we repeated some of these experiments in the presence and absence of 
catalase. A statistically significant dose-dependant decrease of immunoglobulin production 
was observed for all isotypes tested, confirming the results described above. However, there 
were no significant differences in immunoglobulin production between the conditions with 




Our experiments demonstrate that approximately 40% of UVA-1 reaches the dermis where it 
may influence various components including the circulating cells in the capillaries. UVA 
radiation, even in a relatively low dose, appears to be harmful for some white cells. Our 
investigations show that a dose of 2 J/cm2 UVA-1 caused around 20% death of PBMCs. This 
toxic effect further increased with rising UVA-1 doses. However, pre-incubation with catalase 
totally prevented this UVA-1 induced cell death, suggesting that generated hydrogen peroxide 
plays an important role in this UVA-1 induced toxicity. 
Absorption of UVA-1 by its chromophores (like porphyrines or riboflavins) can lead to 
photosensitization reactions that result in production of reactive oxygen species, singlet 
oxygen and superoxide radicals. The latter can undergo dismutation to hydrogen peroxide.18 
Since the highest concentration of the mentioned UVA-1 absorbing compounds is present in 
mitochondria, these organelles are likely to be the most UVA-1 sensitive cellular targets. 
Mitochondrial injury leads to decreased ATP production, which in turn influences 
Chapter 7 






















Figure 7.5. The inhibitory effect of 0.5 or 2 J/cm2 UVA-1 on IgM, IgG, IgA and IgE 
production in supernatants of PBMC cultures activated with CD40L and IL-10, during the 
second week of incubation. Data are expressed as means ± SD of the changes in the 



































































































Figure 7.6. The effect of added catalase on IgM, IgG and IgA production in supernatants of 
PBMC cultures activated with CD40L and IL-10, after 2 J/cm2 UVA-1 during the second 
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 many synthetic processes. Many ATP molecules are necessary for protein synthesis. One can 
expect that even minor oxidative damage of mitochondria in activated B cells could 
consequently lead to decreased protein (immunoglobulin) production. Reactive oxygen 
species can also lead to apoptosis of B cells through activation of the caspase pathway by 
cytochrome c. Singlet oxygen is able to open mitochondrial megachannels, releasing 
apoptosis initiating factor (AIF) and cytochrome c.19 
According to Farber et al.,20 B cells are more sensitive to hydrogen peroxide than T cells. 
In our FACS experiments the sensitivity of three PBMC types was as follows: CD14>CD20 
and CD3 (Fig. 7.3). The B cell population consists of 60 % naïve cells and 40% 
CD27-positive memory B cells.21 Recently, Jacobi et al.22 showed that the number of 
circulating CD27high plasma cells correlated with disease activity in SLE patients. It would be 
interesting to investigate whether there is a difference between the cytotoxic effect of UVA-1 
on different B cell populations. 
A dose-dependent decrease of immunoglobulin production was observed after UVA-1 
radiation in the second week in the IL-10 or IL-4 stimulated conditions. IgE concentrations in 
the supernatants were substantially lower than IgM concentrations (not shown). This can be 
explained by the fact that CD40-CD40L binding with IL-4 stimulation results in B cell 
proliferation and IgE isotype switching, whereas CD40-CD40L binding with IL-10 
stimulation not only gives rise to B cell proliferation and IgG and IgA isotype switching, but 
also to plasma cell differentiation with increased immunoglobulin production. Plasma cell 
differentiation primarily takes place in the second week of cell culture, which explains the fact 
that only very low immunoglobulin concentrations could be measured in both non-irradiated 
and irradiated conditions at day 8 (not shown). 
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Twenty percent of cell death in the PBMC population was observed 24 hours after exposure 
to 2 J/cm2 UVA-1. However, immunoglobulin production following daily irradiations with 
the same dose of UVA-1 in the second week was more than 20% reduced. An impaired B cell 
function could be responsible for this difference, or the cumulative effect of daily irradiations 
resulting in more cell death could be the cause. In the latter situation, the favorable effect 
in vivo could be longer lasting. 
In additional experiments the effect of catalase on immunoglobulin production was 
investigated. Again, a significant dose-dependant decrease of immunoglobulin production 
was observed. However, no significant effect of catalase could be discerned. This observation 
could possibly be explained by the fact that catalase removes hydrogen peroxide exclusively 
extracellularly. This enables it to prevent UVA-1 induced cell death by lipid peroxidation of 
the outer cell membrane, since hydrogen peroxide, in contrast with catalase, can penetrate the 
cell membrane. However, extracellular catalase apparently does not have any profound effect 
on the intracellular concentration of UVA-1 induced hydrogen peroxide. 
Because the epidermis absorbs a considerable portion of UVA-1 irradiation, doses higher than 
2 J/cm2 are probably needed to reach a therapeutic effect. In our clinical studies, we utilized 6 
and 12 J/cm2. According to our penetration experiments, these doses would correspond to 
approximately 2.4 and 4.8 J/cm2 of UVA-1 reaching the dermal capillaries. Therefore, the 
effects of the doses used in our in vitro experiments were relevant to the situation in our 
previous clinical trials. 
In conclusion, we have found evidence that long-wave UVA radiation, after penetration of the 
epidermis, is able to lower the production of antibodies in activated B cells and plasma cells. 
This effect can (partly) explain the clinical improvement observed in SLE patients after 
UVA-1 therapy. 
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In the studies presented in this thesis we investigated the effects of UVA-1 therapy in patients 
with atopic dermatitis, dyshidrotic eczema, generalized lichen planus and systemic lupus 
erythematodes. In this final chapter, the results of these and other studies on UVA-1 therapy 
in these four conditions, as well as reports of UVA-1 therapy in other T cell mediated skin 




UVA-1 has proven effective in the treatment of various T cell mediated diseases, of which 
atopic dermatitis has been studied most extensively. Some authors reported on good results 
obtained by high-dose (130 J/cm2, 3 weeks) UVA-1 in the treatment of atopic dermatitis,1 
whereas others showed that also medium doses (50 J/cm2, 3 weeks) were successful.2 The 
latter appears preferable to minimize the risk of potential long-term side effects. In order to 
better determine the value of UVA-1 in the treatment of atopic dermatitis, not only different 
doses of UVA-1, but also different treatment schedules must be evaluated. Tzaneva et al. 
observed that after the usual successful 3 weeks of medium dose UVA-1 therapy, atopic 
dermatitis deteriorated relatively soon.3 For that reason we investigated whether prolongation 
of the prevailing treatment schedule from 3 to 4 weeks leads to a longer therapeutic result. 
Chapter 2 describes an open prospective study of 32 patients with atopic dermatitis who were 
treated with medium dose UVA-1 radiation (45 J/cm2), 5 days a week, during 4 weeks. Their 
therapeutic effect was retrospectively compared with that of medium dose UVA-1 therapy in 
29 patients who were treated during the usual 3 weeks. Both the SCORAD (scoring atopic 
dermatitis) and the DLQI (dermatology life quality index) improved significantly during both 
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treatment schedules, but at the end of treatment the 4 weeks’ regimen did not prove to be 
more effective than the 3 weeks’ regimen. However, 6 weeks after cessation of therapy 
the patients from the 4 weeks treatment regimen still showed a significant improvement of 
their SCORAD and their DLQI when compared with pre-treatment values, whereas those who 
were treated during 3 weeks did not. We conclude that medium dose UVA-1 therapy can be 
used successfully as a monotherapy in the treatment of atopic dermatitis, with positive effects 
on both disease activity and quality of life. For the prolongation of its remission time, a 
4 weeks’ treatment regimen is preferable to a 3 weeks’ regimen. 
To determine the position of UVA-1 therapy in the treatment of atopic dermatitis, the efficacy 
of UVA-1 therapy should also be compared with other types of phototherapy commonly used 
in atopic dermatitis, such as UVA-UVB combination therapy, PUVA and narrow band 
UVB.4-7 Recent studies showed improvements of disease activity scores of 50% for 
UVA-UVB, of 80% for oral PUVA, of approximately 65% for bath-PUVA and narrow band 
UVB4,5,8 and clearance or near-clearance of disease, in 14 of 15 patients in one study and in 
74% of patients in another study, after oral PUVA.9,10 In several controlled trials, both high- 
and medium-dose UVA-1 proved to be more effective than UVA-UVB combination 
therapy.1,2,11,12 In our patients, the SCORAD improved 49% in the 4 weeks’ treated patients 
and 27% in those treated during 3 weeks. From the results from literature PUVA and narrow 
band UVB appear to be better than UVA-1. However, there have been no controlled studies 
comparing these phototherapeutic modalities so far. 
All mentioned treatment modalities have advantages and disadvantages. Different UV 
therapies have different treatment schedules, which demand different efforts from patients. 
Approximately the same number of treatments is needed for best results of UVA-1, PUVA or 
narrow band UVB therapy. UVA-1 is more time-consuming than PUVA and narrow band 
UVB with irradiations 5 times a week, but it has a shorter treatment period of 4 weeks. 
Chapter 8 
   
118 
 
Although more time-consuming, our experience is that many patients find the UVA-1 therapy 
rather relaxing. They often bring their own music to listen to while lying on the bed in the 
UVA-1 cabin. A disadvantage of these UVA-1 beds is that during irradiations the shadow 
areas in the pubic area and on the sides are not sufficiently treated (unpublished observation). 
Consequently, this kind of UVA-1 cabin is less suitable for treatment of malignant skin 
disorders, like cutaneous T cell lymphomas, for which complete clearance on all sides of the 
body is essential. However, other UVA-1 cabins are comparable to the usual PUVA and UVB 
cabins, and require patients to stand up during therapy. 
Another difference between the treatment options concerns the side effects. Photosensitivity, 
caused by psoralens in PUVA therapy, requires protection of both eyes and skin against 
sunlight during the rest of the day. Furthermore, up to 20% of patients suffer from 
gastrointestinal side effects of oral psoralens.13 In narrow band UVB therapy patients may 
burn more easily, compared with UVA-1 therapy. Apart from a slight erythematous reaction, 
no short-term side effects are usually observed during UVA-1 therapy. Other potential 
short-term side effects for all mentioned phototherapeutic options are induction of UV 
sensitive photodermatoses and herpetic infection. Possible long-term side effects are skin 
aging and development of cutaneous malignancies. Experimental studies (summarized in 
chapter 1) suggest that PUVA and UVB are more mutagenic than UVA-1. However, long-
term follow-up studies to assess skin cancer risk in UVA-1 treated patients have not yet been 
performed. 
Although to our opinion the arguments are in favor of UVA-1 in the treatment of atopic 
dermatitis, the pros and cons should be discussed with the patient, before deciding which 
therapy will be used. 
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Phototherapy also belongs to the standard treatment options of dyshidrotic eczema. Both oral, 
cream-, and bath-PUVA have been reported to have some beneficial effects.14-16 The first 
report on the successful use of UVA-1 in the treatment of chronic dyshidrotic eczema of the 
hands concerned an uncontrolled study of 12 patients.17 They reported 81% improvement of 
the dyshidrosis area and severity index (DASI). However, since the severity of dyshidrotic 
eczema tends to fluctuate and spontaneous remissions may occur, the efficacy of UVA-1 
needed to be established in a controlled manner. In a double blind, placebo controlled study 
(Chapter 3) we investigated 28 patients with dyshidrotic eczema of the hands. The results 
showed a 52% decrease of the DASI, after 3 weeks UVA-1 therapy, whereas after placebo 
treatment the DASI had slightly increased. Thus, UVA-1 treatment proved significantly better 
than placebo therapy.18 In a recent study UVA-1 and PUVA therapy were equally effective.19 
These results further support the efficacy of UVA-1 in the treatment of dyshidrotic eczema. 





Lichen planus (LP) is the third T cell mediated condition we investigated. Although it is 
generally self-limiting, LP may exist for many years, may be generalized and difficult to treat. 
Usually, it occurs on a limited number of localizations, in which case topical treatment 
usually suffices. In generalized LP, local therapy is too laborious and frequently unsuccessful. 
Since the 1970s, beneficial effects of oral photochemotherapy (PUVA) and bath PUVA for 
both localized and generalized LP have been described.20-23 In these publications, clearly 
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defined evaluation parameters were usually lacking, making comparison of results difficult. 
Results were formulated as excellent, good, complete clearance or at least 50% improvement 
in most patients. Furthermore, there was only one small controlled study among them, 
concerning hemi-corporeal oral PUVA therapy in 10 patients,20 and no randomized, 
controlled studies comparing different forms of light therapy have been published so far. 
In chapter 4 we described the favorable effect of UVA-1 therapy in 4 patients with 
therapy-resistant, generalized lichen ruber planus.24 A controlled study was not possible, as 
the generalized form of LP is relatively rare. Patients were treated with 45 J/cm2 for 5 days 
per week during two 4-week treatment periods with a 3-week interval. After UVA-1 therapy 
nearly complete clearance was achieved in 3 patients, and considerable improvement in one. 
However, the tenacious thick plaques on the ankles showed only moderate improvement. 
Both the visual analogue scores for itch and the DLQIs improved considerably in all. In one 
patient, biopsies were taken before and after therapy. Histopathologic results showed that at 
the end of treatment the characteristic features of LP had normalized and only a sparse 
infiltrate remained. Our results, although concerning a limited number of patients, support the 




It has been known for a long time that a large proportion of patients with systemic lupus 
erythematosus (SLE) is sensitive to sunlight25-27 Mainly UVB and, to a lesser extent UVA, are 
held responsible for this photosensitivity.28 Consequently, the first reports of beneficial effects 
of UVA-1 in patients with SLE were rather unexpected. McGrath was the first to show 
clinical improvement in an uncontrolled study of 10 SLE patients.29 This was later confirmed 
by a double blind, placebo controlled, crossover study in 26 patients.30 Unfortunately, both 
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studies were flawed due to use of an inappropriate disease activity scoring system, lack of 
wash out periods risking carry over effects, and failing in correct evaluation of placebo 
effects. Despite the imperfect design, the clinical results appeared interesting enough to 
warrant another double blind placebo controlled study.  
Being aware of the risk of photosensitivity we originally exposed eleven patients with SLE to 
only 6 J/cm2 of UVA-1 and to the same number of minutes of placebo light (see Chapter 5). 
In two consecutive 12-week periods patients were treated with UVA-1 and placebo therapy 
respectively, or vice versa, followed by a 9 weeks’ wash-out period. The primary variables, 
SLE disease activity index (SLEDAI) and SLE activity measure (SLAM) showed a 
significant decrease after three weeks of UVA-1, but not after three weeks of placebo 
treatment. Although the MOS SF36 subscore for vitality improved more during UVA-1 than 
during placebo therapy, the difference was not statistically significant. 
Chapter 6 describes a second study in which we applied a higher dose of 12 J/cm2 in the 
same study design. UVA-1 treatment resulted in a significant decrease of both SLAM and 
SLEDAI at the end of the third week of therapy, whereas neither score improved significantly 
during placebo treatment. Furthermore, when UVA-1 treatment was compared with placebo 
treatment, the decrease of SLAM was statistically significant. However, the decrease of 
SLEDAI was not. 
Two patients in the second study with a history of photosensitivity, experienced transient skin 
reactions at the beginning of UVA-1 therapy, which consisted of a transient facial erythema in 
one and a minimal activation of subacute cutaneous lupus erythematosus (SCLE) in the other. 
In this latter patient the dose was subsequently reduced to 6 J/cm2 at the beginning of the 
second week and the skin changes slowly disappeared. 
In all four patients with anti-SSA antibodies decrease of titres was recorded after UVA-1 
therapy in the first study. In the second study the anti-SSA titre of one patient and the anti-
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RNP titre of another showed a marked decrease, suggesting immunomodulating effects of 
UVA-1 therapy. 
Although the pathogenesis of SLE remains unclear, B lymphocytes are thought to play a 
major role in the immune dysregulation that underlies the disease process.23,31 A significant 
proportion of therapeutic strategies in SLE are based on decreasing the production or the 
selective removal of circulating autoantibodies.23,32,33 Based on this information, the known 
deep penetration of UVA-1 radiation, and the observed decrease of auto antibody titres after 
UVA-1 therapy, we formulated the following hypothesis: UVA-1 induces suppression of 
immunoglobulin production by activated B cells in the dermal capillaries, which could be 
(partly) responsible for the observed improvement of disease activity in patients with SLE. 
In chapter  7 is explained how this hypothesis was confirmed. In order to obtain an estimate 
of the proportion of UVA-1 radiation that can reach the superficial dermis where blood 
capillaries are present, we measured the penetration of UVA-1 through isolated epidermis 
using a UVA-1 measurement device. The average penetration was 39 %, which implies that a 
large part of a given UVA-1 dose is indeed able to reach the superficial dermis and affect the 
function of circulating lymphocytes, monocytes and other cells in the capillary network of the 
skin. The toxic effect of UVA-1 radiation was determined by evaluating the viability of 
irradiated peripheral blood mononuclear cells (PBMCs). A dose as low as 2 J/cm2 UVA-1 
caused around 20% death of PBMCs. This toxic effect further increased with rising UVA-1 
doses. However, pre-incubation with catalase totally prevented this UVA-1-induced cell 
death, suggesting that generated hydrogen peroxide plays an important role in UVA-1 
toxicity. Flow cytometric analysis showed that in comparison with CD20 positive cells 
(B cells) and CD3 positive cells (T cells), CD14 positive cells (monocytes) seem to be the 
cells most sensitive to UVA-1.  
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A dose-dependent decrease of IgM, IgG, IgA and IgE production was observed after UVA-1 
radiation of PBMCs in a well-established CD40-CD40L B cell activation system with IL-10 
or IL-4 stimulation. Twenty percent of cell death in the PBMC population was observed 
24 hours after exposure to 2 J/cm2 UVA-1. However, a 47%, 44%, 36% and 60% decrease of 
IgM, IgG, IgA and IgE production, respectively, was observed following daily irradiations of 
PBMC cultures with the same dose of UVA-1. It is very likely that UVA-1 irradiation causes 
not only B cell apoptosis, but also affects immunoglobulin production of the surviving 
B cells. In addition, the cumulative effect of daily irradiations may bring about more cell 
death and even more decreased immunoglobulin production. 
Whereas pre-incubation with catalase totally prevented UVA-1-induced cell death, no 
convincing effect of catalase on immunoglobulin production could be discerned. This could 
possibly be explained by the fact that catalase removes hydrogen peroxide exclusively 
extracellularly. This enables it to prevent UVA-1 induced cell death by lipid peroxidation of 
the outer cell membrane, since hydrogen peroxide, in contrast with catalase, can penetrate the 
cell membrane. However, extracellular catalase apparently does not have any profound effect 
on the intracellular concentration of UVA-1 induced hydrogen peroxide. 
The observed effect of UVA-1 on immunoglobulin production suggests that UVA-1 therapy 
could also be effective in the treatment of other auto-immune diseases, apart from SLE. 
A likely prerequisite for success in the disease in question is the presence of activated 
circulating B cells and plasma cells in dermal capillaries. However, not all auto-immune 
diseases have B cells or plasma cells that produce antibodies outside the spleen and lymph 
nodes. A relevant auto-immune disease could be Sjögren’s syndrome, in which the presence 
of antibody-producing cells in the peripheral blood has already been demonstrated.34 In the 
treatment of SLE it is important to realize that this disease can be activated by UV radiation. 
Furthermore, different UVA-1 lamps have different emission spectra. Treatment with lamps 
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emitting even very small amounts of UVB should be avoided, because this radiation could 
cause apoptosis of epidermal keratinocytes with consequent activation of the auto-immune 
process. 
In conclusion, we have found evidence that long-wave UVA radiation is able to lower the 
production of antibodies by activated B cells and plasma cells. This observation can, at least 
partly, explain the clinical improvement observed in SLE patients after UVA-1 therapy. 
 
UVA-1 for other T cell mediated skin diseases 
 
Apart from the four (skin) diseases discussed before, there are several case reports and small 
uncontrolled studies reporting on the beneficial effects of UVA-1 therapy in various other 
T cell mediated skin disorders. The results of these studies are summarized in Table 1. The 
results of UVA-1 therapy in sclerotic skin diseases are of particular interest and are discussed 
in more detail below. 
 
Sclerotic skin diseases 
Since the mid-1990s several reports on the effect of UVA-1 on localized scleroderma 
(morphea) have been published. Induction of interstitial matrix metalloproteinases (MMP), 
especially collagenase (MMP-1) is held responsible for hydrolysis of collagen in the skin after 
UVA-1 therapy, leading to improvement of sclerotic skin diseases.35-37 Apart from 
collagenase induction and T cell apoptosis,38 increased vascular endothelial growth factor 
(VEGF) expression and reduced apoptotic endothelial cell turnover may also contribute to 
amelioration of disease activity by improving vascularization.39 In one study, after 
30 exposures, high dose (130 J/cm2, n=10) was superior to low dose (20 J/cm2, n=7) UVA-1 
therapy. High dose UVA-1 therapy resulted in obvious reduction and softening of sclerotic 
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plaques, decreased skin thickness measured by 20 MHz ultrasound, and decreased skin 
elasticity determined by elastometry.54 Nevertheless, others reported complete clearance of 
80% of the lesions in 10 patients after 24 irradiations with only 20 J/cm2, 4 times a week for 
6 weeks, and disappearance or marked improvement of 80% of sclerotic lesions in 18 out of 
20 patients after 30 treatments with 20 J/cm2.55,56  
Also in patients with systemic sclerosis, softening of skin lesions on forearms and hands, 
improved passive range of motion of hand and wrist joints, improved cutaneous elasticity, and 
healing of ulcerations were observed.57-59 Some small studies and case reports were published 
on the effect of UVA-1 on some other sclerotic skin diseases like extragenital lichen 
sclerosus, sclerodermic graft-versus-host disease of the skin, scleredema, keloid, and 
nephrogenic fibrosing dermopathy.60-66 Although we have only limited experience in UVA-1 
treatment of patients with keloids and scleredema, we could not fully confirm the reported 
positive effects in these patients. PUVA therapy has been found effective in the treatment of 
both localized scleroderma and systemic sclerosis as well.67-69 To our knowledge, no studies 
























































































































































































































































































































































































































































































































































































































































































































































































































































UVA-1 radiation is a useful therapeutic option for various T cell mediated and sclerotic skin 
diseases. We think that UVA-1 is the phototherapy of choice in atopic dermatitis and 
dyshidrotic eczema, and that this treatment could be a valuable therapeutic option in patients 
with generalized lichen planus and sclerotic skin diseases. To minimize potential carcinogenic 
risks, medium dose UVA-1 regimen are preferable to high dose regimen. Controlled studies 
are needed for further validation of the place of UVA-1 therapy in the dermatological 
practice. Interesting possibilities for future research comprise the effect of UVA-1 therapy in 
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UVA-1 therapy is a relatively new form of light therapy. Since the beginning of the 1990s, the 
therapeutic effects of long wave UVA sources have been investigated in patients with atopic 
dermatitis. One of the mechanisms behind the positive effect of UVA-1 therapy in these 
patients is the UVA-1-induced apoptosis of T cells in the dermal inflammatory infiltrate. 
During the 1990s the number of indications for UVA-1 light therapy has substantially 
increased. Mostly T cell mediated conditions were investigated with the use of  “low dose” 
(around 10 J/cm2), as well as “medium dose” (around 45 J/cm2), and “high dose” UVA-1 
(around 130 J/cm2). 
 
In chapter 2, the investigation of the efficacy of medium dose (45 J/cm2) UVA-1 in  patients 
with atopic dermatitis is described. Since it is known that after the customary treatment 
schedule of 15 irradiations during 3 subsequent weeks deterioration of atopic dermatitis can 
occur relatively soon, we investigated if prolongation of therapy with one week will result in 
better clinical outcome. Both the SCORAD (scoring atopic dermatitis) and the DLQI 
(dermatology life quality index, a validated quality of life score) improved significantly 
during both the 3 and the 4 weeks´ treatment regimen. There was no difference between both 
groups. However, 6 weeks after therapy the patients from the 4 weeks’ treatment regimen still 
showed a significant improvement of their SCORAD and their DLQI compared to 
pre-treatment values, whereas those who were treated during 3 weeks did not. 
In chapter 3 successful UVA-1 therapy in patients with dyshidrotic eczema is described. The 
effect of UVA-1 therapy was investigated in a double blind, placebo controlled study. UVA-1 
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therapy proved to be significantly better than placebo therapy, adding dishydrotic eczema to 
the T cell mediated indications for UVA-1 light therapy. 
Lichen ruber planus, a T cell mediated condition as well, usually occurs only on the 
predilection places, in which case it is treated  topically. However, if it manifests itself as a 
generalized skin disorder, local therapy is impractical. In chapter 4 we described the 
favorable effect of UVA-1 therapy in patients with chronic, generalized lichen ruber planus. 
Moreover, this chapter documents the toxic effect of UVA-1 monotherapy on the cells that 
form the typical dermal inflammatory infiltrate. UVA-1 therapy can be a good alternative for 
this extensive form. 
Since UVA-1 has proven to be effective in the treatment of dermal T cell mediated 
conditions, it is to be expected that UVA-1 could easily penetrate to the dermal capillaries and 
affect there circulating cells. Except for T cells, B cells could also be influenced. Systemic 
lupus erythematosus (SLE) is characterized by the production of auto-antibodies by activated 
B-lymphocytes, giving rise to inflammation in various organs. The usual therapeutic options 
involve systemic corticosteroids, azathioprine, and cyclophosphamide but can be 
accompanied by various, possibly serious side-effects. 
On account of the well-known risk of photosensitivity, we initially investigated the effect of 
merely 6 J/cm2 UVA-1, in a double blinded, placebo controlled, cross-over study (chapter 5). 
After 3 weeks, this treatment resulted in decrease of both the SLE activity measure (SLAM) 
and the SLE disease activity index (SLEDAI), two validated methods used for the 
determination of disease activity in SLE patients. Although the UVA-1 treatment resulted in 
the improvement of clinical scores, the difference between the UVA-1 effect and the placebo 
effect was not statistically significant.  
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To investigate whether a higher dose has a better effect we treated SLE patients with 12 J/cm2 
in a second study with a similar experimental design (chapter 6). After 3 weeks of 12 J/cm2 
UVA-1, both the SLAM and SLEDAI had significantly improved. Additionally, UVA-1 
therapy proved to be more effective than placebo treatment, when measured by the SLAM. 
In both in vivo studies an effect on auto-antibody titers was observed. Apart from problems of 
temporary photosensitivity in some and slight activation of subacute cutaneous lupus 
erythematosus (SCLE) in one patient, no side effects occurred. With these controlled studies 
we confirmed the positive effects of UVA-1 radiation in the treatment of patients with 
moderately active SLE (chapter 5 and 6). The auto-antibody profile of the patients was very 
heterogeneous, which is often the case with SLE patients. Nevertheless, a clear decreasing 
trend was observed in the anti-SSA titers after UVA-1 treatment in the first study.  
This observation and the decrease of the anti-RNP and anti-SSA titers of the 2 patients in the 
second study encouraged us to investigate the effect of UVA-1 on the immunoglobulin 
production by B cells in vitro (chapter 7). Toxic effect on activated B cells and plasma cells 
in the dermal capillaries could result in decreased immunoglobulin production with 
consequent improvement of disease activity in SLE patients. 
First, we measured the UVA-1 penetration through the epidermis. It turned out that 
approximately 40% of UVA-1 could reach the dermal cells. Then, we wanted to find out how 
sensitive B lymphocytes were to UVA-1 cytotoxicity. Twenty-four hours after irradiation 
with rising doses of UVA-1 we found increasing numbers of PBMCs to be dead. 
Pre-incubation of the cultured cells with catalase, which breaks down hydrogen peroxide, 
prevented the cell death completely. Determination of UVA-1 cytotoxicity for different 
PBMC subpopulations showed that the monocytes were the most sensitive to UVA-1 
radiation.  
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Finally, we investigated the effect of UVA-1 radiation on immunoglobulin production by 
activated B cells of healthy individuals. The IgM-, IgG- and the IgE production decreased 
with increasing doses of UVA-1, in IL-10 or IL-4 stimulated conditions. A similar effect on 
the IgA production was also visible, but did not reach statistic significance. 
Although in the in vitro  part 20% of PBMCs died after 6 J/cm2 of UVA-1, this was not 
enough to fully explain the observed reduction of IgM and IgE production. We suggested that 
the toxic effect of UVA-1 can also cause a reduction of B cell function. We believe that the 
production of hydrogen peroxide plays an important role in these toxic effects of UVA-1 
radiation. 
 
In conclusion, UVA-1 can be effective not only in T cell mediated diseases, but also in B cell 
mediated conditions, like systemic lupus erythemadosus. It would be interesting to investigate 
the possibility of using UVA-1 therapy for other auto-immune diseases. However, a necessary 






UVA-1 therapie is een relatief nieuwe vorm van lichttherapie. Sinds begin jaren 90 wordt het 
therapeutisch effect van de langgolvige UVA bronnen onderzocht bij patiënten met 
consitutioneel eczeem. De voornaamste verklaring voor het positieve effect van UVA-1 
therapie bij deze patiënten is de UVA-1 geïnduceerde apoptose van T cellen in het dermale 
ontstekingsinfiltraat. In de loop van de jaren negentig is het aantal indicaties voor UVA-1 
lichttherapie fors toegenomen. Veelal T-cel gemedieerde aandoeningen worden in deze 
periode onderzocht, waarbij zowel “low dose” (rond 10 J/cm2), “medium dose” (rond 
45 J/cm2), als “high dose” UVA-1 (rond 130 J/cm2) wordt gebruikt. 
 
In hoofdstuk 2 hebben wij de werkzaamheid van medium dosis (45 J/cm2) UVA-1 bij 
patiënten met constitutioneel eczeem getoetst. Omdat na het meest gangbare behandelschema, 
van 15 belichtingen gedurende 3 weken, relatief snel een recidief van de klachten kan 
optreden, hebben wij onderzocht of verlenging van de therapieduur met 1 week tot betere 
resultaten leidt. Zowel de SCORAD (scoring atopic dermatitis) als de DLQI (dermatology life 
quality index, een gevalideerde kwaliteit van leven score) verbeterden significant gedurende 
zowel de 3 weken als de 4 weken durende kuur. Er kon geen verschil worden aangetoond 
tussen de beide groepen. Wel waren de 4 weken behandelde patiënten, in tegenstelling tot de 
3 weken behandelde patiënten, in staat een significante verbetering te behouden tijdens 
6 weken follow-up. 
In hoofdstuk 3 wordt de succesvolle UVA-1 therapie van patiënten met dyshidrotisch eczeem 
beschreven. Het effect van UVA-1 therapie werd onderzocht in een dubbel blinde, placebo 
gecontroleerde studie. UVA-1 therapie bleek significant beter dan placebo behandeling, 
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waarmee dyshidrotisch eczeem kon worden toegevoegd aan de T-cel gemedieerde indicaties 
voor UVA-1 lichttherapie.  
Lichen ruber planus, eveneens een T-cel gemedieerde aandoening, is meestal slechts op de 
predilectieplaatsen gelocaliseerd en wordt dan locaal behandeld. Wanneer er sprake is van een 
gegeneraliseerde vorm is locale therapie niet praktisch. In hoofdstuk 4 beschreven wij het 
positieve effect van UVA-1 therapie bij patiënten met chronische, gegeneraliseerde lichen 
ruber planus. In dit hoofdstuk wordt bovendien het toxische effect van UVA-1 monotherapie 
op het lymfocytaire infiltraat gedemonstreerd. UVA-1 lichttherapie kan bij deze uitgebreide 
vorm een goed alternatief zijn.  
Aangezien UVA-1 effectief is gebleken in de behandeling van dermale T cel gemedieerde 
aandoeningen, kan men verwachten dat UVA-1 ook in staat zou kunnen zijn de dermale 
capillairen te bereiken en de daarin circulerende cellen te beïnvloeden. Behalve T cellen 
zouden ook B cellen beïnvloed kunnen worden. Systemische lupus erythematodes (SLE) 
wordt gekenmerkt door de productie van auto-antilichamen door geactiveerde B-lymfocyten, 
wat aanleiding geeft tot inflammatie in diverse organen. De gebruikelijke therapeutische 
mogelijkheden, zoals systemische corticosteroïden, azathioprine en cyclofosfamide kunnen 
gepaard gaan met verscheidene, mogelijk ernstige bijwerkingen. 
Vanwege het bekende risico op fotosensitiviteit onderzochten wij in eerste instantie het effect 
van slechts 6 J/cm2 UVA-1, in een dubbel blinde, placebo gecontroleerde, cross-over studie 
(hoofdstuk 5). Deze behandeling resulteerde na 3 weken in een verlaging van zowel de SLE 
activity measure (SLAM) als de SLE disease acitivity index (SLEDAI), twee gevalideerde 
methodes om ziekteactiviteit van SLE patiënten te meten. Het verschil met het effect van 
placebo behandeling was echter niet statistisch significant. 
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Met de vraag of een hogere dosis een beter effect heeft werden in een tweede studie volgens 
de zelfde opzet SLE patiënten behandeld met 12 J/cm2 (hoofdstuk 6). Na 3 weken 
behandeling met 12 J/cm2 UVA-1 werd een significante verbetering gezien van zowel de 
SLAM als de SLEDAI. Bovendien bleek UVA-1 behandeling significant beter dan placebo 
behandeling, gemeten volgens de SLAM. In beide in vivo studies werd een effect op 
auto-antilichamen titers waargenomen. Behoudens problemen van passagère fotosensitiviteit 
bij enkelen en geringe activatie van subacute cutane lupus erythematosus (SCLE) bij een 
patiënt, traden tijdens beide studies geen bijwerkingen op.  
In deze gecontroleerde studies kon bevestigd worden dat UVA-1 een gunstig effect kan 
hebben in de behandeling van matig actieve SLE (hoofdstuk 5 en 6). Het auto-antilichamen 
profiel van de patiënten was erg heterogeen, zoals vaak het geval is bij SLE patiënten. 
Desondanks werd een duidelijke negatieve trend gezien in de anti-SSA titers na UVA-1 
behandeling in de eerste studie.  
Deze waarneming en de afname van de anti-RNP titer en de anti-SSA titer van twee patiënten 
in de tweede studie, brachten ons ertoe in een in vitro studie het effect van UVA-1 op de 
immunoglobuline productie door B cellen te onderzoeken (hoofdstuk 7). Toxisch effect op de 
geactiveerde B-lymfocyten en plasmacellen in de bloedcapillairen van de huid zou kunnen 
resulteren in afname van immunoglobuline productie met als mogelijk gevolg vermindering 
van de ziekteactiviteit van SLE patiënten. 
Ten eerste werd de penetratie van UVA-1 door de epidermis bepaald. Ongeveer 40% van het 
UVA-1 bleek de dermis te kunnen bereiken. Vervolgens was het belangrijk te weten hoe 
gevoelig B-lymfocyten zijn voor het cytotoxische effect van UVA-1. Vierentwintig uur na 
belichting met UVA-1 bleek bij oplopende doses UVA-1 een toenemend aantal perifere bloed 
mononucleaire cellen (PBMCs) dood te gaan. Na pre-incubatie van de celkweken met 
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catalase, hetgeen waterstofperoxide afbreekt, werd celdood volledig voorkomen. Bij 
onderzoek naar de toxiciteit van UVA-1 voor verschillende subpopulaties van de PBMCs, 
bleek de monocyten populatie de meest gevoelige voor UVA-1 cytotoxiciteit. 
Tenslotte werd naar het effect van UVA-1 op de immunoglobuline productie door 
geactiveerde B-lymfocyten van gezonde proefpersonen gekeken. De IgM-, IgG- en de IgE 
productie nam af bij oplopende doses UVA-1, in de IL-10 of IL-4 gestimuleerde condities. 
Een vergelijkbaar, doch niet statistisch significant, effect was waarneembaar op de IgA 
productie. 
Hoewel in onze in vitro studie 20% van de PBMCs dood ging na 6 J/cm2 UVA-1, was dit te 
weinig om de waargenomen afname van IgM en IgE productie onder invloed van deze zelfde 
dosis volledig te verklaren. Behalve celdood speelt mogelijk ook UVA-1 geïnduceerde 
afname van B-cel functie een rol. Waarschijnlijk speelt de productie van waterstofperoxide 
een belangrijke rol in het tot stand komen van deze toxische effecten van UVA-1 straling. 
 
Samenvattend kan UVA-1 behalve bij de behandeling van T cel gemedieerde aandoeningen 
ook effectief zijn in de behandeling van een B cel gemedieerde ziekte als systemische lupus 
erythematodes. Het zou interessant zijn de effectiviteit van UVA-1 lichttherapie bij andere 
auto-immuunziekten systematisch te onderzoeken. Een voorwaarde is echter dat bij deze 
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